pamidronate and Pain
pamidronate has been researched along with Pain in 138 studies
Pain: An unpleasant sensation induced by noxious stimuli which are detected by NERVE ENDINGS of NOCICEPTIVE NEURONS.
Research Excerpts
| Excerpt | Relevance | Reference |
|---|---|---|
| "To assess outcomes of young patients with osteonecrosis (ON) treated with pamidronate in terms of relief of pain, prevention of progress and bony collapse of involved area." | 9.12 | Pamidronate treatment of steroid associated osteonecrosis in young patients treated for acute lymphoblastic leukaemia--two-year outcomes. ( Nguyen, T; Zacharin, MR, 2006) |
| "This study evaluated whether additional palliative benefits could be derived from the second-line use of the more potent bisphosphonate zoledronic acid in metastatic breast cancer patients with either progressive bone metastases or skeletal-related events (SRE), despite first-line therapy with either pamidronate or clodronate." | 9.12 | Phase II trial evaluating the palliative benefit of second-line zoledronic acid in breast cancer patients with either a skeletal-related event or progressive bone metastases despite first-line bisphosphonate therapy. ( Clemons, MJ; Cole, DE; Dranitsaris, G; Ooi, WS; Pritchard, KI; Sukovic, T; Trudeau, M; Verma, S; Wong, BY; Yogendran, G, 2006) |
| "Clinical studies showed that pamidronate has curative effects on pain induced by bone metastasis." | 9.11 | [Pamidronate in treatment of pain caused by bone metastasis]. ( Cai, Y; Chen, YL; Liu, HQ; Liu, MZ; Ren, J; Wang, DJ; Zhan, QY, 2004) |
| "5) nonambulatory children with cerebral palsy or a neuromuscular disorder received cyclic intravenous administration of pamidronate." | 9.11 | Cyclic administration of pamidronate to treat osteoporosis in children with cerebral palsy or a neuromuscular disorder: a clinical study. ( Allington, N; Gerard, P; Vivegnis, D, 2005) |
| "To evaluate the clinical therapeutic value of (188)Re-HEDP combined with pamidronate in breast cancer with bone metastasis." | 9.11 | [Clinical value of combined therapy with 188Re-HEDP and pamidronate in breast cancer with bone metastasis]. ( Chen, SX; DU, JQ; Jiang, NY; Liang, JG; Liu, XG; Lu, XP, 2005) |
| "Thirteen patients with McCune-Albright syndrome (MAS) and bone fibrous dysplasia (BFD) have been treated for 2-6 years with pamidronate, an aminobisphosphonate which inhibits osteoclastic function." | 9.10 | Pamidronate treatment in bone fibrous dysplasia in children and adolescents with McCune-Albright syndrome. ( Altare, F; Andreo, M; de Sanctis, C; Lala, R; Masi, G; Matarazzo, P, 2002) |
| " To evaluate the therapeutic effects of Disodium Pamidronate (Bonin) on bone pain in multiple myeloma." | 9.10 | [Effects of pamidronate disodium (Bonin) combined with chemotherapy on bone pain in multiple myeloma]. ( Chen, SL; Leng, Y; Shi, HZ, 2002) |
| " There were no sustained significant differences between the pamidronate and placebo groups in self-reported pain measurements, analgesic use, proportion of patients with an SRE, or mobility at week 9 or 27." | 9.10 | Combined analysis of two multicenter, randomized, placebo-controlled studies of pamidronate disodium for the palliation of bone pain in men with metastatic prostate cancer. ( Kowalski, MO; Petrone, S; Seaman, JJ; Small, EJ; Smith, MR, 2003) |
| "13 patients with treatment-resistant multiple myeloma with advanced osteolytic lesions received combined pamidronate and thalidomide therapy." | 9.10 | Combination of pamidronate and thalidomide in the therapy of treatment-resistant multiple myeloma. ( Baran, W; Ciepłuch, H; Hellmann, A, 2002) |
| "The aim of this double-blind, randomized study was to compare the effects of two pamidronate dosages, given as repeated infusions in patients with advanced malignant osteolytic bone disease and bone pain." | 9.09 | Pamidronate treatment in patients with malignant osteolytic bone disease and pain: a prospective randomized double-blind trial. ( Bacchus, L; Koeberle, D; Senn, HJ; Thuerlimann, B, 1999) |
| "Patients with stage III multiple myeloma and at least one lytic lesion received either placebo or pamidronate (90 mg) as a four-hour intravenous infusion given every four weeks for nine cycles in addition to antimyeloma therapy." | 9.08 | Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma. Myeloma Aredia Study Group. ( Ballester, O; Bell, R; Berenson, JR; Blacklock, HA; Bordoni, R; Dimopoulos, MA; George, S; Heffernan, M; Keller, A; Knight, RD; Kovacs, MJ; Lichtenstein, A; Lipton, A; Porter, L; Reitsma, DJ; Seaman, J; Simeone, J, 1996) |
| " 40 patients with progressing painful bone metastases received 45 mg pamidronate by 1-h infusion every 3 weeks." | 9.08 | Pamidronate in patients with painful bone metastases, who failed initial treatment with hormones and/or chemotherapy. ( Alessandroni, P; Casadei, V; Cascinu, S; Catalano, G; Del Ferro, E, 1996) |
| "Pamidronate, an aminobisphosphonate, has been shown to lower the risk of skeletal complications associated with lytic bone lesions for up to 1 year in women with stage IV breast cancer who received chemotherapy." | 9.08 | Long-term prevention of skeletal complications of metastatic breast cancer with pamidronate. Protocol 19 Aredia Breast Cancer Study Group. ( Blayney, D; Heffernan, M; Hortobagyi, GN; Knight, RD; Lipton, A; Mellars, K; Porter, L; Reitsma, DJ; Seaman, JJ; Simeone, JF; Sinoff, C; Theriault, RL; Wheeler, H, 1998) |
| "In an uncontrolled observational study involving 30 children who were 3 to 16 years old and had severe osteogenesis imperfecta, we administered pamidronate intravenously (mean [+/-SD] dose, 6." | 9.08 | Cyclic administration of pamidronate in children with severe osteogenesis imperfecta. ( Bishop, NJ; Chabot, G; Glorieux, FH; Lanoue, G; Plotkin, H; Travers, R, 1998) |
| "47 patients with progressive, painful, predominantly lytic bone metastases from breast cancer were included in a randomised double-blind phase II trial comparing the effects of pamidronate 150 and 300 mg daily." | 9.08 | A randomised phase II study of oral pamidronate for the treatment of bone metastases from breast cancer. ( Coleman, RE; Ford, J; Houston, S; Kandra, A; Purohit, OP; Rubens, RD, 1998) |
| " Pamidronate disodium, a bisphosphonate, may prove helpful in the palliative treatment of bone metastases in patients with breast cancer as demonstrated in this multicenter, dose-ranging trial." | 9.07 | Intravenous pamidronate disodium treatment of bone metastases in patients with breast cancer. A dose-seeking study. ( Browning, S; Fram, RJ; George, S; Glover, D; Keller, A; Lipton, A; Macerata, RS; Miller, AA; Seaman, JJ; Zelenakas, K, 1994) |
| "Selective aspects of quality of life during supportive pamidronate (APD) treatment were assessed in breast cancer patients with osteolytic metastases." | 9.07 | The effect of supportive pamidronate treatment on aspects of quality of life of patients with advanced breast cancer. ( Aaronson, NK; Bijvoet, OL; Cleton, FJ; Hermans, J; van Dam, FS; van den Bos, B; van Emmerik, B; van Holten-Verzantvoort, AT; Zwinderman, AH, 1991) |
| "To explore the effects of pamidronate disodium combined with calcium on BMD values and the severity of pain in elderly patients with osteoporosis based on the mobile terminal platform for the Internet of Things." | 8.12 | Effects of Pamidronate Disodium Combined with Calcium on BMD Values and Severity of Pain in Elderly Patients with Osteoporosis Based on Mobile Terminal Platform for Internet of Things. ( Bai, Z; Guo, P; Kang, M; Wang, D; Wang, J, 2022) |
| "To investigate if intravenous pamidronate improves bone density in a cohort of patients with chronic neurological conditions and low bone density, in whom fractures and bone pain are impacting on care." | 7.76 | Pamidronate improves pain, wellbeing, fracture rate and bone density in 14 children and adolescents with chronic neurological conditions. ( Davis, E; Howe, W; Valentine, J, 2010) |
| "To evaluate the effect of intravenous pamidronate therapy on everyday activities, well-being, skeletal pain and bone density in children with osteogenesis imperfecta (OI)." | 7.74 | Effect of intravenous pamidronate therapy on everyday activities in children with osteogenesis imperfecta. ( Aström, E; Eliasson, AC; Löwing, K; Oscarsson, KA; Söderhäll, S, 2007) |
| "To evaluate reported cases of scleritis and other ocular side effects associated with pamidronate disodium, with emphasis on previously unreported cases of scleritis." | 7.72 | Scleritis and other ocular side effects associated with pamidronate disodium. ( Fraunfelder, FT; Fraunfelder, FW; Jensvold, B, 2003) |
| " We studied patterns of pagetic pain in relation to physical activity, and the effect of coexistent osteoarthritis (OA)/pagetic arthropathy on pain and physical activity before and after treatment with pamidronate." | 7.72 | Patterns of pain in Paget's disease of bone and their outcomes on treatment with pamidronate. ( Mehan, R; Miller, H; Swinson, DR; Talwalkar, A; Vasireddy, S, 2003) |
| "To report the clinical experience with pamidronate in childhood SAPHO syndrome." | 7.72 | Pamidronate in the treatment of childhood SAPHO syndrome. ( Beresford, MW; Cleary, AG; Davidson, JE; Kerrison, C, 2004) |
| "A 62-yr-old woman with thyroid carcinoma metastatic to bone, and a history of subclinical hypoparathyroidism was admitted to the hospital in hypocalcemic crisis 5 wk after receiving iv pamidronate." | 7.71 | Prolonged, symptomatic hypocalcemia with pamidronate administration and subclinical hypoparathyroidism. ( Jonklaas, J; Mishra, A; Wong, L, 2001) |
| "Pamidronate treatment improves bone quality in children with mild types of OI." | 6.71 | Pamidronate treatment of less severe forms of osteogenesis imperfecta in children. ( Kanumakala, S; Zacharin, M, 2004) |
| "Pamidronate was well tolerated in the majority of the patients both during the first six infusions and during the whole study period." | 6.70 | The role of disodium pamidronate in the management of bone pain due to malignancy. ( Boffi, R; Brunelli, C; Cazzaniga, M; De Conno, F; Groff, L; Panzeri, C; Ripamonti, C; Zecca, E, 2001) |
| "Pamidronate treatment also did not have any influence on patient survival or on the frequency of hypercalcaemia." | 6.69 | Failure of oral pamidronate to reduce skeletal morbidity in multiple myeloma: a double-blind placebo-controlled trial. Danish-Swedish co-operative study group. ( Abildgaard, N; Brincker, H; Ford, J; Gimsing, P; Hedenus, M; Kandra, A; Turesson, I; Westin, J, 1998) |
| "Pamidronate is an easy to use potent inhibitor of osteolysis, given in conjunction with standard anticancer therapies effectively relieves bone pain and improves performance status." | 6.41 | [Pamidronate in the treatment of bone metastases from breast cancer]. ( Gyuricska, A; Landherr, L; Nagykálnai, T; Zatkóné, GP, 2002) |
| " Oral etidronate given daily showed no clinical benefit, whereas the use of oral clodronate daily did reduce the development of new osteolytic lesions but did not significantly affect bone pain or rates of pathologic fractures." | 6.18 | Bisphosphonates in multiple myeloma. ( Berenson, JR, 1997) |
| "Treatment with pamidronate is beneficial for the patient, family and society, increases mobility and bone density, improves quality of life and reduces family dependence in children with OI." | 5.46 | Therapy with pamidronate in children with osteogenesis imperfecta. ( Brad, GF; Mang, N; Marginean, O; Mozos, I; Tamasanu, RC, 2017) |
| "Zoledronic acid also attenuated mechanical hyperalgesia associated with chronic peripheral neuropathy and inflammation in the rat." | 5.31 | Disease modifying and anti-nociceptive effects of the bisphosphonate, zoledronic acid in a model of bone cancer pain. ( Bowes, M; Chan, O; Fox, AJ; Glatt, M; Green, J; Kesingland, A; Kidd, BL; McNair, K; Medhurst, SJ; Patel, S; Urban, LA; Walker, K, 2002) |
| "Treatment with pamidronate, an inhibitor of osteoclastic bone resorption, given every 2 weeks by i." | 5.31 | Pamidronate-induced remission of pain associated with hypertrophic pulmonary osteoarthropathy in chemoendocrine therapy-refractory inoperable metastatic breast carcinoma. ( Naito, Y; Sakurai, T; Suzuma, T; Tamaki, T; Umemura, T; Yoshimasu, T; Yoshimura, G, 2001) |
| "Our study confirmed that pamidronate, prednisone, and guideline-recommended anticonvulsants were effective for reducing pain intensity for CPSP." | 5.22 | Pharmacotherapies for Central Post-Stroke Pain: A Systematic Review and Network Meta-Analysis. ( Bo, Z; Gangfeng, G; Jian, W; Jian, Y; Ke, H; Maoxia, L; Xiaojing, L; Xiaolan, L; Yan, L; Yang, F; Zhao, C, 2022) |
| "Bisphosphonate use, in particular pamidronate, improved pain scores, analgesic requirement and musculoskeletal function in patients with osteonecrosis occurring as a complication of childhood ALL therapy." | 5.14 | Use of bisphosphonates for the treatment of osteonecrosis as a complication of therapy for childhood acute lymphoblastic leukaemia (ALL). ( Carter, T; Cole, C; Kotecha, RS; Lee, SJ; Murray, KJ; Powers, N, 2010) |
| "Patients with either progressive bone metastases or SREs while on clodronate or pamidronate may experience significant pain palliation with a switch to a more potent bisphosphonate." | 5.13 | A Phase II trial evaluating the palliative benefit of second-line oral ibandronate in breast cancer patients with either a skeletal related event (SRE) or progressive bone metastases (BM) despite standard bisphosphonate (BP) therapy. ( Clemons, M; Cole, DE; Dranitsaris, G; Ooi, W, 2008) |
| "Our aim was to compare the analgesic efficacy of pamidronate (PAM) and synthetic human calcitonin (CT) in intravenous infusion for recent painful benign vertebral compression in a randomised prospective double-blind study." | 5.12 | Comparison of the analgesic efficacy of pamidronate and synthetic human calcitonin in osteoporotic vertebral fractures: a double-blind controlled study. ( Cantagrel, A; Cantogrel, S; Constantin, A; Jamard, B; Laroche, M; Mazières, B; Zabraniecki, L, 2006) |
| "To assess outcomes of young patients with osteonecrosis (ON) treated with pamidronate in terms of relief of pain, prevention of progress and bony collapse of involved area." | 5.12 | Pamidronate treatment of steroid associated osteonecrosis in young patients treated for acute lymphoblastic leukaemia--two-year outcomes. ( Nguyen, T; Zacharin, MR, 2006) |
| "It was established that in the course of pamidronate infusion therapy BE levels remained constant, whereas the values in serum alkaline phosphatase and pain intensity scores were significantly reduced." | 5.12 | The analgesic effect of pamidronate is not caused by the elevation of beta endorphin level in Paget's disease--a controlled pilot study. ( Barna, I; Bender, T; Donáth, J; Gergely, P; Poór, G, 2006) |
| "This study evaluated whether additional palliative benefits could be derived from the second-line use of the more potent bisphosphonate zoledronic acid in metastatic breast cancer patients with either progressive bone metastases or skeletal-related events (SRE), despite first-line therapy with either pamidronate or clodronate." | 5.12 | Phase II trial evaluating the palliative benefit of second-line zoledronic acid in breast cancer patients with either a skeletal-related event or progressive bone metastases despite first-line bisphosphonate therapy. ( Clemons, MJ; Cole, DE; Dranitsaris, G; Ooi, WS; Pritchard, KI; Sukovic, T; Trudeau, M; Verma, S; Wong, BY; Yogendran, G, 2006) |
| "Data concerning the suspension of new skeletal complications, as well as the apparent improvement of overall survival, pain score and ECOG status, suggest that the pamidronate-treatment should not be stopped once started." | 5.11 | Duration of bisphosphonate treatment: results of a non-randomised study in patients previously treated with local irradiation for bone metastases from breast cancer. ( Balafouta, M; Gennatas, C; Kokakis, J; Kouloulias, VE; Kouvaris, JR; Mystakidou, K; Pistevou-Gombaki, K; Varela, MN; Vlahos, LJ, 2004) |
| "Clinical studies showed that pamidronate has curative effects on pain induced by bone metastasis." | 5.11 | [Pamidronate in treatment of pain caused by bone metastasis]. ( Cai, Y; Chen, YL; Liu, HQ; Liu, MZ; Ren, J; Wang, DJ; Zhan, QY, 2004) |
| "5) nonambulatory children with cerebral palsy or a neuromuscular disorder received cyclic intravenous administration of pamidronate." | 5.11 | Cyclic administration of pamidronate to treat osteoporosis in children with cerebral palsy or a neuromuscular disorder: a clinical study. ( Allington, N; Gerard, P; Vivegnis, D, 2005) |
| "To evaluate the clinical therapeutic value of (188)Re-HEDP combined with pamidronate in breast cancer with bone metastasis." | 5.11 | [Clinical value of combined therapy with 188Re-HEDP and pamidronate in breast cancer with bone metastasis]. ( Chen, SX; DU, JQ; Jiang, NY; Liang, JG; Liu, XG; Lu, XP, 2005) |
| "Thirteen patients with McCune-Albright syndrome (MAS) and bone fibrous dysplasia (BFD) have been treated for 2-6 years with pamidronate, an aminobisphosphonate which inhibits osteoclastic function." | 5.10 | Pamidronate treatment in bone fibrous dysplasia in children and adolescents with McCune-Albright syndrome. ( Altare, F; Andreo, M; de Sanctis, C; Lala, R; Masi, G; Matarazzo, P, 2002) |
| " To evaluate the therapeutic effects of Disodium Pamidronate (Bonin) on bone pain in multiple myeloma." | 5.10 | [Effects of pamidronate disodium (Bonin) combined with chemotherapy on bone pain in multiple myeloma]. ( Chen, SL; Leng, Y; Shi, HZ, 2002) |
| " There were no sustained significant differences between the pamidronate and placebo groups in self-reported pain measurements, analgesic use, proportion of patients with an SRE, or mobility at week 9 or 27." | 5.10 | Combined analysis of two multicenter, randomized, placebo-controlled studies of pamidronate disodium for the palliation of bone pain in men with metastatic prostate cancer. ( Kowalski, MO; Petrone, S; Seaman, JJ; Small, EJ; Smith, MR, 2003) |
| "Pamidronate at 60 mg was compared with pamidronate at 10 mg rather than placebo in view of the high incidence of transient arthralgias upon first IV exposure to the drug." | 5.10 | A six-month randomized, controlled, double-blind, dose-response comparison of intravenous pamidronate (60 mg versus 10 mg) in the treatment of nonsteroidal antiinflammatory drug-refractory ankylosing spondylitis. ( Aaron, SL; Chiu, P; Davis, P; Fitzgerald, AA; Homik, J; Jhangri, GS; LeClercq, S; Maksymowych, WP; Russell, AS; Sholter, D; Skeith, KJ; Yan, A, 2002) |
| "13 patients with treatment-resistant multiple myeloma with advanced osteolytic lesions received combined pamidronate and thalidomide therapy." | 5.10 | Combination of pamidronate and thalidomide in the therapy of treatment-resistant multiple myeloma. ( Baran, W; Ciepłuch, H; Hellmann, A, 2002) |
| "The aim of this double-blind, randomized study was to compare the effects of two pamidronate dosages, given as repeated infusions in patients with advanced malignant osteolytic bone disease and bone pain." | 5.09 | Pamidronate treatment in patients with malignant osteolytic bone disease and pain: a prospective randomized double-blind trial. ( Bacchus, L; Koeberle, D; Senn, HJ; Thuerlimann, B, 1999) |
| "Patients with stage III multiple myeloma and at least one lytic lesion received either placebo or pamidronate (90 mg) as a four-hour intravenous infusion given every four weeks for nine cycles in addition to antimyeloma therapy." | 5.08 | Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma. Myeloma Aredia Study Group. ( Ballester, O; Bell, R; Berenson, JR; Blacklock, HA; Bordoni, R; Dimopoulos, MA; George, S; Heffernan, M; Keller, A; Knight, RD; Kovacs, MJ; Lichtenstein, A; Lipton, A; Porter, L; Reitsma, DJ; Seaman, J; Simeone, J, 1996) |
| " 40 patients with progressing painful bone metastases received 45 mg pamidronate by 1-h infusion every 3 weeks." | 5.08 | Pamidronate in patients with painful bone metastases, who failed initial treatment with hormones and/or chemotherapy. ( Alessandroni, P; Casadei, V; Cascinu, S; Catalano, G; Del Ferro, E, 1996) |
| " Anderson, the use of the recently approved bisphosphonate pamidronate (Aredia) became a part of the standard of care pathway for the treatment of osteolytic metastases from breast cancer." | 5.08 | Fitting new modalities into practice guidelines. ( Theriault, RL, 1997) |
| "Pamidronate, an aminobisphosphonate, has been shown to lower the risk of skeletal complications associated with lytic bone lesions for up to 1 year in women with stage IV breast cancer who received chemotherapy." | 5.08 | Long-term prevention of skeletal complications of metastatic breast cancer with pamidronate. Protocol 19 Aredia Breast Cancer Study Group. ( Blayney, D; Heffernan, M; Hortobagyi, GN; Knight, RD; Lipton, A; Mellars, K; Porter, L; Reitsma, DJ; Seaman, JJ; Simeone, JF; Sinoff, C; Theriault, RL; Wheeler, H, 1998) |
| "In an uncontrolled observational study involving 30 children who were 3 to 16 years old and had severe osteogenesis imperfecta, we administered pamidronate intravenously (mean [+/-SD] dose, 6." | 5.08 | Cyclic administration of pamidronate in children with severe osteogenesis imperfecta. ( Bishop, NJ; Chabot, G; Glorieux, FH; Lanoue, G; Plotkin, H; Travers, R, 1998) |
| "47 patients with progressive, painful, predominantly lytic bone metastases from breast cancer were included in a randomised double-blind phase II trial comparing the effects of pamidronate 150 and 300 mg daily." | 5.08 | A randomised phase II study of oral pamidronate for the treatment of bone metastases from breast cancer. ( Coleman, RE; Ford, J; Houston, S; Kandra, A; Purohit, OP; Rubens, RD, 1998) |
| " Pamidronate disodium, a bisphosphonate, may prove helpful in the palliative treatment of bone metastases in patients with breast cancer as demonstrated in this multicenter, dose-ranging trial." | 5.07 | Intravenous pamidronate disodium treatment of bone metastases in patients with breast cancer. A dose-seeking study. ( Browning, S; Fram, RJ; George, S; Glover, D; Keller, A; Lipton, A; Macerata, RS; Miller, AA; Seaman, JJ; Zelenakas, K, 1994) |
| "Selective aspects of quality of life during supportive pamidronate (APD) treatment were assessed in breast cancer patients with osteolytic metastases." | 5.07 | The effect of supportive pamidronate treatment on aspects of quality of life of patients with advanced breast cancer. ( Aaronson, NK; Bijvoet, OL; Cleton, FJ; Hermans, J; van Dam, FS; van den Bos, B; van Emmerik, B; van Holten-Verzantvoort, AT; Zwinderman, AH, 1991) |
| "Pamidronate, along with other bisphosphonates, has been used for treatment of bone pain secondary to malignant involvement or metastatic disease for years." | 4.85 | Pamidronate treatment in rheumatology practice: a comprehensive review. ( Boulman, N; Feld, J; Odeh, M; Rimar, D; Rosner, I; Rozenbaum, M; Slobodin, G, 2009) |
| " They now constitute the standard treatment for cancer hypercalcemia, for which we recommend a dose of 1,500 mg of clodronate or 90 mg of pamidronate; the latter compound is more potent and has a longer lasting effect." | 4.80 | Current use of bisphosphonates in oncology. International Bone and Cancer Study Group. ( Bartl, R; Body, JJ; Burckhardt, P; Delmas, PD; Diel, IJ; Fleisch, H; Kanis, JA; Kyle, RA; Mundy, GR; Paterson, AH; Rubens, RD, 1998) |
| " In multiple myeloma, one study with oral clodronate has reported a decrease in bone events and two other studies, one with intravenous pamidronate and the other with oral clodronate have both reported a decrease in skeletal events and bone pain." | 4.80 | [Bisphosphonates and bone metastases]. ( Berthaud, P; Jadaud, E; Lortholary, A, 1999) |
| " As regards pamidronate, several open, controlled studies have shown a significant effect on bone pain in 30-70% of breast cancer patients." | 4.79 | Analgesic effect of bisphosphonates on bone pain in breast cancer patients: a review article. ( Strang, P, 1996) |
| "To explore the effects of pamidronate disodium combined with calcium on BMD values and the severity of pain in elderly patients with osteoporosis based on the mobile terminal platform for the Internet of Things." | 4.12 | Effects of Pamidronate Disodium Combined with Calcium on BMD Values and Severity of Pain in Elderly Patients with Osteoporosis Based on Mobile Terminal Platform for Internet of Things. ( Bai, Z; Guo, P; Kang, M; Wang, D; Wang, J, 2022) |
| " Bone cancer was induced by intra-tibial injections of murine mammary carcinoma cells (4T1) in immunocompetent BALB/c mice and treated intraperitoneally for up to 5 weeks with vehicle, rapamycin or pamidronate (a bisphosphonate currently used to reduce bone loss in bone cancer patients)." | 3.80 | Osteolysis and pain due to experimental bone metastases are improved by treatment with rapamycin. ( Abdelaziz, DM; Komarova, SV; Stone, LS, 2014) |
| "To investigate if intravenous pamidronate improves bone density in a cohort of patients with chronic neurological conditions and low bone density, in whom fractures and bone pain are impacting on care." | 3.76 | Pamidronate improves pain, wellbeing, fracture rate and bone density in 14 children and adolescents with chronic neurological conditions. ( Davis, E; Howe, W; Valentine, J, 2010) |
| "To evaluate the effect of intravenous pamidronate therapy on everyday activities, well-being, skeletal pain and bone density in children with osteogenesis imperfecta (OI)." | 3.74 | Effect of intravenous pamidronate therapy on everyday activities in children with osteogenesis imperfecta. ( Aström, E; Eliasson, AC; Löwing, K; Oscarsson, KA; Söderhäll, S, 2007) |
| "To evaluate reported cases of scleritis and other ocular side effects associated with pamidronate disodium, with emphasis on previously unreported cases of scleritis." | 3.72 | Scleritis and other ocular side effects associated with pamidronate disodium. ( Fraunfelder, FT; Fraunfelder, FW; Jensvold, B, 2003) |
| "Intravenous infusions with the bisphosphonate compound pamidronate decrease bone pain and reportedly can lead to refilling of dysplastic lesions in adults with fibrous dysplasia (FD) of bone." | 3.72 | Effect of pamidronate treatment in children with polyostotic fibrous dysplasia of bone. ( Glorieux, FH; Munns, C; Plotkin, H; Rauch, F; Travers, R; Zeitlin, L, 2003) |
| " We studied patterns of pagetic pain in relation to physical activity, and the effect of coexistent osteoarthritis (OA)/pagetic arthropathy on pain and physical activity before and after treatment with pamidronate." | 3.72 | Patterns of pain in Paget's disease of bone and their outcomes on treatment with pamidronate. ( Mehan, R; Miller, H; Swinson, DR; Talwalkar, A; Vasireddy, S, 2003) |
| "To report the clinical experience with pamidronate in childhood SAPHO syndrome." | 3.72 | Pamidronate in the treatment of childhood SAPHO syndrome. ( Beresford, MW; Cleary, AG; Davidson, JE; Kerrison, C, 2004) |
| " Intravenous pamidronate treatment given monthly for a year was well tolerated and produced dramatic clinical effects, with reduction in bone pain and improvements in mobility, despite incomplete suppression of bone resorption as assessed by biochemical, radiographic and histological criteria." | 3.71 | The osteodystrophy of mucolipidosis type III and the effects of intravenous pamidronate treatment. ( Baker, N; Cundy, T; David, G; Hofman, P; King, A; Noble, J; Robinson, C; Sillence, D, 2002) |
| ") (brittle bone disease) is primarily supportive; early introduction of cyclic intravenous pamidronate administration in children younger than 2 years of age is an innovative and promising therapeutic approach." | 3.71 | [Osteogenesis imperfecta: a new, early therapeutic approach with biphosphonates. A case report]. ( al-Jazayri, Z; Amiour, M; Desrosieres, H; Eckart, P; Guillot, M, 2001) |
| "A 62-yr-old woman with thyroid carcinoma metastatic to bone, and a history of subclinical hypoparathyroidism was admitted to the hospital in hypocalcemic crisis 5 wk after receiving iv pamidronate." | 3.71 | Prolonged, symptomatic hypocalcemia with pamidronate administration and subclinical hypoparathyroidism. ( Jonklaas, J; Mishra, A; Wong, L, 2001) |
| "Three children (ages 9 to 11 years) with osteoporosis pseudoglioma syndrome who had multiple vertebral collapse were treated over a 2-year period with intermittent intravenous bisphosphonate infusions (pamidronate in 2, clodronate in 1)." | 3.70 | Osteoporosis pseudoglioma syndrome: treatment of spinal osteoporosis with intravenous bisphosphonates. ( Cundy, T; Zacharin, M, 2000) |
| " One of the earliest agents to be investigated, etidronate, is effective in the management of malignant hypercalcemia and, when used orally and intermittently, results in reduced bone loss in osteoporosis." | 3.69 | Role of bisphosphonates in prevention and treatment of bone metastases from breast cancer. ( Ashley, S; Hanson, J; Kanis, JA; McCloskey, E; Paterson, AH; Powles, TJ, 1995) |
| " We performed a clinical study to evaluate the therapeutic effect of Disodium Pamidronate over pain and radiologic evolution in bone metastases (Breast Cancer and Multiple Myeloma patients)." | 3.68 | [Disodium pamidronate (APD) in the treatment of bone metastases]. ( Costa, L; da Costa, EB; Moreira, C, 1993) |
| "One of the main features of McCune-Albright syndrome is bone fibrous dysplasia (BFD) often associated with severe clinical outcomes, such as bone pain, bone deformities and pathological fractures." | 2.72 | Bisphosphonate treatment of bone fibrous dysplasia in McCune-Albright syndrome. ( Andreo, M; Bellone, J; Corrias, A; de Sanctis, C; Lala, R; Marzari, D; Matarazzo, P, 2006) |
| "Pamidronate treatment improves bone quality in children with mild types of OI." | 2.71 | Pamidronate treatment of less severe forms of osteogenesis imperfecta in children. ( Kanumakala, S; Zacharin, M, 2004) |
| "Skeletal metastases from thyroid cancer are poorly responsive to medical or radioiodine treatment." | 2.70 | Pamidronate improves the quality of life and induces clinical remission of bone metastases in patients with thyroid cancer. ( Abbruzzese, A; Caraglia, M; Ciccarelli, A; Fonderico, F; Lupoli, G; Martignetti, A; Nuzzo, V; Vitale, G, 2001) |
| "Bone resorption was assessed by measurement of urinary collagen crosslinks." | 2.70 | Comparison of the effects of intravenous pamidronate and oral clodronate on symptoms and bone resorption in patients with metastatic bone disease. ( Coleman, RE; Heatley, S; Herling, C; Jagdev, SP; Purohit, P, 2001) |
| "Pamidronate was well tolerated in the majority of the patients both during the first six infusions and during the whole study period." | 2.70 | The role of disodium pamidronate in the management of bone pain due to malignancy. ( Boffi, R; Brunelli, C; Cazzaniga, M; De Conno, F; Groff, L; Panzeri, C; Ripamonti, C; Zecca, E, 2001) |
| "Pamidronate treatment also did not have any influence on patient survival or on the frequency of hypercalcaemia." | 2.69 | Failure of oral pamidronate to reduce skeletal morbidity in multiple myeloma: a double-blind placebo-controlled trial. Danish-Swedish co-operative study group. ( Abildgaard, N; Brincker, H; Ford, J; Gimsing, P; Hedenus, M; Kandra, A; Turesson, I; Westin, J, 1998) |
| "Pamidronate is a bisphosphonate whose short-term biological efficacy in Paget's disease of bone was convincingly established many years ago." | 2.69 | Effect of multiple intravenous pamidronate courses in Paget's disease of bone. ( Arlot, M; Meunier, PJ; Thevenon, J; Trombetti, A; Uebelhart, B, 1999) |
| "We have evaluated the value of specific bone resorption markers in monitoring metastatic bone disease to define the duration of action of a single high-dose pamidronate infusion." | 2.68 | Metabolic effects of pamidronate in patients with metastatic bone disease. ( Coleman, RE; Eastell, R; Guo, CY; Purohit, OP; Vinholes, J, 1996) |
| " In a randomized phase III trial of 377 patients with multiple myeloma, Aredia was administered in a dosage of 90 mg i." | 2.68 | The role of bisphosphonates in the treatment of bone metastases--the U.S. experience. ( Harvey, HA; Lipton, A, 1996) |
| "Pamidronate is a safe, welltolerated, and effective treatment for Paget's disease." | 2.68 | Clinical, biochemical, hematologic, and radiographic responses in Paget's disease following intravenous pamidronate disodium: a 2-year study. ( Bhagat, CI; Gutteridge, DH; Kent, GN; Nicholson, GC; Price, RI; Prince, RL; Retallack, RW; Stewart, GO; Stuckey, BG; Thompson, RI; Ward, LC, 1996) |
| "Pamidronate is a second generation bisphosphonate that has been used in Europe for the treatment of Paget's disease of bone for several years." | 2.67 | Effects of intravenous pamidronate therapy on Paget's disease of bone. ( Bombassei, GJ; Raisz, LG; Yocono, M, 1994) |
| " We have evaluated the effectiveness of three dosage regimes of aminohydroxypropylidene bisphosphonate (pamidronate) in 15 patients with extensive Paget's disease who had become refractory to conventional therapy." | 2.67 | Pamidronate is effective for Paget's disease of bone refractory to conventional therapy. ( Gunasekera, RD; Wimalawansa, SJ, 1993) |
| "There was a significant reduction in pathological fractures and severe bone pain in the APD group, and hypercalcaemia was prevented." | 2.66 | Reduced morbidity from skeletal metastases in breast cancer patients during long-term bisphosphonate (APD) treatment. ( Beex, LV; Bijvoet, OL; Cleton, FJ; Elte, JW; Harinck, HI; Hermans, J; Kroon, HM; Neijt, JP; van Holten-Verzantvoort, AT; Vermey, P, 1987) |
| "Pain is one of the most common symptoms in children and young people (CYP) with life-limiting conditions (LLCs) which include a wide range of diagnoses including cancer." | 2.52 | Pharmacological interventions for pain in children and adolescents with life-limiting conditions. ( Beecham, E; Bluebond-Langner, M; Candy, B; Howard, R; Jones, L; Laddie, J; McCulloch, R; Rees, H; Vickerstaff, V, 2015) |
| "Pamidronate is an easy to use potent inhibitor of osteolysis, given in conjunction with standard anticancer therapies effectively relieves bone pain and improves performance status." | 2.41 | [Pamidronate in the treatment of bone metastases from breast cancer]. ( Gyuricska, A; Landherr, L; Nagykálnai, T; Zatkóné, GP, 2002) |
| "Management of ankylosing spondylitis (AS) is challenged by the progressive nature of the disease." | 2.41 | Conventional treatments for ankylosing spondylitis. ( Brandt, J; Dijkmans, B; Dougados, M; Khan, M; Maksymowych, W; van der Linden, S, 2002) |
| "Zoledronic acid (4 mg) has been compared to placebo in a randomized Phase III trial involving 422 men with hormone-refractory prostate cancer metastatic to bone." | 2.41 | The new bisphosphonate, Zometa (zoledronic acid), decreases skeletal complications in both osteolytic and osteoblastic lesions: a comparison to pamidronate. ( Gleason, D; Gordon, D; Kowalski, MO; Lipton, A; Reitsma, D; Rosen, L; Saad, F; Seaman, J; Small, E; Smith, M, 2002) |
| "Myelomatosis is associated with considerable skeletal morbidity, particularly bone pain and fractures." | 2.41 | Bisphosphonates in multiple myeloma. ( Kanis, JA; McCloskey, EV, 2000) |
| "Patients with breast cancer associated solely with osseous metastasis may live for a number of years." | 2.41 | Treatment of metastatic bone disease in breast cancer: bisphosphonates. ( Bastert, G; Diel, IJ; Solomayer, EF, 2000) |
| "Tramadol is a centrally acting analgesic drug; it has an agonist effect on mu 1 receptors of opioids and acts also by inhibiting the re-uptake of noradrenaline and serotonine which activates descending monoaminergic inhibitory pathways." | 2.40 | [Treatment of pain in oncology]. ( De Conno, F; Polastri, D, 1997) |
| "Pamidronate is a second-generation aminobisphosphonate that is a much more potent inhibitor of osteoclastic activity." | 2.40 | Bisphosphonates and breast carcinoma. ( Lipton, A, 1997) |
| "Experts in the field were approached." | 2.40 | Should bisphosphonates be part of the standard therapy of patients with multiple myeloma or bone metastases from other cancers? An evidence-based review. ( Bloomfield, DJ, 1998) |
| "The variability of different breast cancers in the susceptibility to metastatic bone disease is poorly understood." | 2.39 | Rationale for the use of bisphosphonates in breast cancer. ( Kanis, JA, 1996) |
| "Treatment with pamidronate is beneficial for the patient, family and society, increases mobility and bone density, improves quality of life and reduces family dependence in children with OI." | 1.46 | Therapy with pamidronate in children with osteogenesis imperfecta. ( Brad, GF; Mang, N; Marginean, O; Mozos, I; Tamasanu, RC, 2017) |
| "In total, 55,864 women with breast cancer were included, with 307,467 person-years of follow-up." | 1.35 | Use of intravenous bisphosphonates in older women with breast cancer. ( Duan, Z; Fang, S; Giordano, SH; Goodwin, JS; Hortobagyi, GN; Kuo, YF, 2008) |
| "Pamidronate treatment (60 mg/day for 3 days) was repeated in patients without evidence of PDB remission at day 120." | 1.32 | Risedronate and pamidronate treatment in the clinical management of patients with severe Paget's disease of bone and acquired resistance to bisphosphonates. ( Mossetti, G; Nunziata, V; Rendina, D; Sorrentino, M; Viceconti, R, 2004) |
| "Zoledronic acid also attenuated mechanical hyperalgesia associated with chronic peripheral neuropathy and inflammation in the rat." | 1.31 | Disease modifying and anti-nociceptive effects of the bisphosphonate, zoledronic acid in a model of bone cancer pain. ( Bowes, M; Chan, O; Fox, AJ; Glatt, M; Green, J; Kesingland, A; Kidd, BL; McNair, K; Medhurst, SJ; Patel, S; Urban, LA; Walker, K, 2002) |
| "Pamidronate was the most popular choice of drug, but a number of respondents chose to use clodronate, often on the basis of cost saving." | 1.31 | Use of bisphosphonates for the treatment of metastatic bone pain. A survey of palliative physicians in the UK. ( Johnson, IS, 2001) |
| "Treatment with pamidronate, an inhibitor of osteoclastic bone resorption, given every 2 weeks by i." | 1.31 | Pamidronate-induced remission of pain associated with hypertrophic pulmonary osteoarthropathy in chemoendocrine therapy-refractory inoperable metastatic breast carcinoma. ( Naito, Y; Sakurai, T; Suzuma, T; Tamaki, T; Umemura, T; Yoshimasu, T; Yoshimura, G, 2001) |
| "To find an effective symptomatic treatment for osteogenesis imperfecta (OI)." | 1.31 | Beneficial effect of long term intravenous bisphosphonate treatment of osteogenesis imperfecta. ( Aström, E; Söderhäll, S, 2002) |
| "The baseline levels of bone resorption markers were used to predict the probability of non-progressive bone disease or reduction in pain intensity during bisphosphonate therapy." | 1.30 | Diagnostic and prognostic value of biochemical markers in malignant bone disease: a prospective study on the effect of bisphosphonate on pain intensity and progression of malignant bone disease. ( Engler, H; Koeberle, D; Riesen, WF; Senn, HJ; Thuerlimann, B, 1998) |
Research
Studies (138)
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (0.72) | 18.7374 |
| 1990's | 50 (36.23) | 18.2507 |
| 2000's | 71 (51.45) | 29.6817 |
| 2010's | 13 (9.42) | 24.3611 |
| 2020's | 3 (2.17) | 2.80 |
Authors
| Authors | Studies |
|---|---|
| Bai, Z | 1 |
| Wang, J | 1 |
| Kang, M | 1 |
| Guo, P | 1 |
| Wang, D | 1 |
| Bo, Z | 1 |
| Jian, Y | 1 |
| Yan, L | 1 |
| Gangfeng, G | 1 |
| Xiaojing, L | 1 |
| Xiaolan, L | 1 |
| Zhao, C | 1 |
| Ke, H | 1 |
| Yang, F | 1 |
| Maoxia, L | 1 |
| Jian, W | 1 |
| Fraleigh, R | 1 |
| Wei, XC | 1 |
| Yu, W | 1 |
| Miettunen, PM | 1 |
| Marginean, O | 1 |
| Tamasanu, RC | 1 |
| Mang, N | 1 |
| Mozos, I | 1 |
| Brad, GF | 1 |
| Van Poznak, C | 1 |
| Somerfield, MR | 1 |
| Moy, B | 1 |
| Lee, KC | 1 |
| Ferguson, BM | 1 |
| Abdelaziz, DM | 1 |
| Stone, LS | 1 |
| Komarova, SV | 1 |
| Addison, CL | 1 |
| Bouganim, N | 1 |
| Hilton, J | 1 |
| Vandermeer, L | 1 |
| Dent, S | 1 |
| Amir, E | 1 |
| Hopkins, S | 1 |
| Kuchuk, I | 1 |
| Segal, R | 1 |
| Song, X | 1 |
| Gertler, S | 1 |
| Mazzarello, S | 1 |
| Dranitsaris, G | 3 |
| Ooi, D | 1 |
| Pond, G | 1 |
| Clemons, M | 2 |
| Beecham, E | 1 |
| Candy, B | 1 |
| Howard, R | 1 |
| McCulloch, R | 1 |
| Laddie, J | 1 |
| Rees, H | 1 |
| Vickerstaff, V | 1 |
| Bluebond-Langner, M | 1 |
| Jones, L | 1 |
| Liao, M | 1 |
| Magcalas, P | 1 |
| Hopkins-Braddock, P | 1 |
| Amin, NL | 1 |
| James, RM | 1 |
| Phillips, R | 1 |
| Giordano, SH | 1 |
| Fang, S | 1 |
| Duan, Z | 1 |
| Kuo, YF | 1 |
| Hortobagyi, GN | 3 |
| Goodwin, JS | 1 |
| Osanai, T | 1 |
| Tsuchiya, T | 1 |
| Sugawara, M | 1 |
| Slobodin, G | 1 |
| Rosner, I | 1 |
| Feld, J | 1 |
| Rimar, D | 1 |
| Rozenbaum, M | 1 |
| Boulman, N | 1 |
| Odeh, M | 1 |
| Howe, W | 1 |
| Davis, E | 1 |
| Valentine, J | 1 |
| Kotecha, RS | 1 |
| Powers, N | 1 |
| Lee, SJ | 1 |
| Murray, KJ | 1 |
| Carter, T | 1 |
| Cole, C | 1 |
| Heras, P | 1 |
| Hatzopoulos, A | 1 |
| Heras, V | 1 |
| Kritikos, N | 1 |
| Karagiannis, S | 1 |
| Kritikos, K | 1 |
| Weinstein, E | 1 |
| Arnold, RM | 1 |
| Joerger, M | 1 |
| Templeton, A | 1 |
| Köberle, D | 1 |
| Engler, H | 2 |
| Riesen, WF | 2 |
| Thürlimann, B | 2 |
| Matarazzo, P | 2 |
| Lala, R | 2 |
| Masi, G | 1 |
| Andreo, M | 2 |
| Altare, F | 1 |
| de Sanctis, C | 2 |
| Nagykálnai, T | 1 |
| Landherr, L | 1 |
| Zatkóné, GP | 1 |
| Gyuricska, A | 1 |
| Dougados, M | 1 |
| Dijkmans, B | 1 |
| Khan, M | 1 |
| Maksymowych, W | 1 |
| van der Linden, S | 1 |
| Brandt, J | 1 |
| Pistevou-Gombaki, K | 2 |
| Eleftheriadis, N | 1 |
| Sofroniadis, I | 1 |
| Makris, P | 1 |
| Kouloulias, V | 1 |
| Lipton, A | 7 |
| Small, E | 1 |
| Saad, F | 1 |
| Gleason, D | 1 |
| Gordon, D | 1 |
| Smith, M | 1 |
| Rosen, L | 1 |
| Kowalski, MO | 2 |
| Reitsma, D | 1 |
| Seaman, J | 2 |
| Leng, Y | 1 |
| Chen, SL | 1 |
| Shi, HZ | 1 |
| Petcu, EB | 1 |
| Schug, SA | 1 |
| Smith, H | 1 |
| Walker, K | 1 |
| Medhurst, SJ | 1 |
| Kidd, BL | 1 |
| Glatt, M | 1 |
| Bowes, M | 1 |
| Patel, S | 1 |
| McNair, K | 1 |
| Kesingland, A | 1 |
| Green, J | 1 |
| Chan, O | 1 |
| Fox, AJ | 1 |
| Urban, LA | 1 |
| Major, PP | 1 |
| Cook, R | 1 |
| Fraunfelder, FW | 1 |
| Fraunfelder, FT | 1 |
| Jensvold, B | 1 |
| Robinson, C | 1 |
| Baker, N | 1 |
| Noble, J | 1 |
| King, A | 1 |
| David, G | 1 |
| Sillence, D | 2 |
| Hofman, P | 1 |
| Cundy, T | 2 |
| Myers, B | 1 |
| Plotkin, H | 2 |
| Rauch, F | 1 |
| Zeitlin, L | 1 |
| Munns, C | 2 |
| Travers, R | 2 |
| Glorieux, FH | 2 |
| Small, EJ | 1 |
| Smith, MR | 1 |
| Seaman, JJ | 4 |
| Petrone, S | 1 |
| Kelly, WK | 1 |
| Steineck, G | 1 |
| Vasireddy, S | 1 |
| Talwalkar, A | 1 |
| Miller, H | 1 |
| Mehan, R | 1 |
| Swinson, DR | 1 |
| Walsh, JP | 1 |
| Ward, LC | 2 |
| Stewart, GO | 2 |
| Will, RK | 1 |
| Criddle, RA | 1 |
| Prince, RL | 2 |
| Stuckey, BG | 2 |
| Dhaliwal, SS | 1 |
| Bhagat, CI | 2 |
| Retallack, RW | 2 |
| Kent, GN | 2 |
| Drury, PJ | 1 |
| Vasikaran, S | 1 |
| Gutteridge, DH | 2 |
| Rendina, D | 1 |
| Mossetti, G | 1 |
| Viceconti, R | 1 |
| Sorrentino, M | 1 |
| Nunziata, V | 1 |
| Kouloulias, VE | 1 |
| Kouvaris, JR | 1 |
| Mystakidou, K | 1 |
| Varela, MN | 1 |
| Kokakis, J | 1 |
| Balafouta, M | 1 |
| Gennatas, C | 1 |
| Vlahos, LJ | 1 |
| Chapurlat, RD | 2 |
| Hugueny, P | 1 |
| Delmas, PD | 4 |
| Meunier, PJ | 6 |
| Kerrison, C | 1 |
| Davidson, JE | 1 |
| Cleary, AG | 1 |
| Beresford, MW | 1 |
| Díaz, C | 1 |
| Soutelo, MJ | 1 |
| Quiroga, L | 1 |
| Palmer, L | 1 |
| Lutfi, R | 1 |
| Perkins, P | 1 |
| Curtin, NJ | 1 |
| Green, AR | 1 |
| Booth, S | 1 |
| Wang, DJ | 1 |
| Liu, HQ | 1 |
| Ren, J | 1 |
| Chen, YL | 1 |
| Zhan, QY | 1 |
| Cai, Y | 1 |
| Liu, MZ | 1 |
| Zacharin, M | 2 |
| Kanumakala, S | 1 |
| Tanvetyanon, T | 1 |
| Allington, N | 1 |
| Vivegnis, D | 1 |
| Gerard, P | 1 |
| Liang, JG | 1 |
| Jiang, NY | 1 |
| DU, JQ | 1 |
| Lu, XP | 1 |
| Liu, XG | 1 |
| Chen, SX | 1 |
| Laroche, M | 1 |
| Cantogrel, S | 1 |
| Jamard, B | 1 |
| Constantin, A | 1 |
| Zabraniecki, L | 1 |
| Cantagrel, A | 1 |
| Mazières, B | 1 |
| Nguyen, T | 1 |
| Zacharin, MR | 1 |
| Bayram, F | 1 |
| Tanriverdi, F | 1 |
| Kurtoğlu, S | 1 |
| Atabek, ME | 1 |
| Kula, M | 1 |
| Kaynar, L | 1 |
| Keleştimur, F | 1 |
| Marzari, D | 1 |
| Bellone, J | 1 |
| Corrias, A | 1 |
| Bender, T | 1 |
| Donáth, J | 1 |
| Barna, I | 1 |
| Gergely, P | 1 |
| Poór, G | 1 |
| Bhansali, A | 1 |
| Singh, R | 1 |
| Sriraam, M | 1 |
| Bhadada, S | 1 |
| Clemons, MJ | 1 |
| Ooi, WS | 1 |
| Yogendran, G | 1 |
| Sukovic, T | 1 |
| Wong, BY | 1 |
| Verma, S | 1 |
| Pritchard, KI | 1 |
| Trudeau, M | 1 |
| Cole, DE | 2 |
| Ooi, W | 1 |
| Löwing, K | 1 |
| Aström, E | 2 |
| Oscarsson, KA | 1 |
| Söderhäll, S | 2 |
| Eliasson, AC | 1 |
| Merlotti, D | 1 |
| Gennari, L | 1 |
| Martini, G | 1 |
| Valleggi, F | 1 |
| De Paola, V | 1 |
| Avanzati, A | 1 |
| Nuti, R | 1 |
| Poujol, D | 1 |
| Ristori, JM | 1 |
| Dubost, JJ | 1 |
| Soubrier, M | 1 |
| George, R | 1 |
| Hephzibah, J | 1 |
| John, S | 1 |
| Yamada, K | 1 |
| Kohno, N | 1 |
| Gleeson, H | 1 |
| Wiltshire, E | 1 |
| Briody, J | 1 |
| Hall, J | 1 |
| Chaitow, J | 1 |
| Cowell, C | 1 |
| Glover, D | 1 |
| Keller, A | 2 |
| Miller, AA | 1 |
| Browning, S | 1 |
| Fram, RJ | 1 |
| George, S | 2 |
| Zelenakas, K | 1 |
| Macerata, RS | 1 |
| Siris, ES | 1 |
| Chakravarty, K | 1 |
| Merry, P | 1 |
| Scott, DG | 1 |
| Liens, D | 2 |
| Bombassei, GJ | 1 |
| Yocono, M | 1 |
| Raisz, LG | 1 |
| Purohit, OP | 4 |
| Anthony, C | 1 |
| Radstone, CR | 1 |
| Owen, J | 1 |
| Coleman, RE | 6 |
| Morant, R | 1 |
| Jungi, WF | 1 |
| Radziwill, A | 1 |
| Wimalawansa, SJ | 1 |
| Gunasekera, RD | 1 |
| Costa, L | 1 |
| Moreira, C | 1 |
| da Costa, EB | 1 |
| Berenson, JR | 2 |
| Lichtenstein, A | 1 |
| Porter, L | 2 |
| Dimopoulos, MA | 1 |
| Bordoni, R | 1 |
| Ballester, O | 1 |
| Kovacs, MJ | 1 |
| Blacklock, HA | 1 |
| Bell, R | 1 |
| Simeone, J | 2 |
| Reitsma, DJ | 3 |
| Heffernan, M | 3 |
| Knight, RD | 3 |
| Kanis, JA | 5 |
| Vinholes, J | 1 |
| Guo, CY | 1 |
| Eastell, R | 1 |
| Harvey, HA | 1 |
| Cascinu, S | 1 |
| Casadei, V | 1 |
| Del Ferro, E | 1 |
| Alessandroni, P | 1 |
| Catalano, G | 1 |
| Collange, C | 1 |
| Brantus, JF | 1 |
| Sidot, C | 1 |
| Paterson, AH | 2 |
| Powles, TJ | 1 |
| McCloskey, E | 1 |
| Hanson, J | 1 |
| Ashley, S | 1 |
| Price, RI | 1 |
| Thompson, RI | 1 |
| Nicholson, GC | 1 |
| Body, JJ | 4 |
| Piccart, M | 1 |
| McBride, G | 1 |
| Marshall, A | 1 |
| Kavanagh, RT | 1 |
| Crisp, AJ | 1 |
| Strang, P | 1 |
| Hultborn, R | 1 |
| Gundersen, S | 1 |
| Rydén, S | 1 |
| Holmberg, E | 1 |
| Carstensen, J | 1 |
| Wallgren, UB | 1 |
| Kilany, S | 1 |
| De Conno, F | 2 |
| Polastri, D | 1 |
| Weinstein, RS | 1 |
| Ciana, G | 1 |
| Cuttini, M | 1 |
| Bembi, B | 1 |
| Vinholes, JJ | 1 |
| Zekri, J | 1 |
| Theriault, RL | 3 |
| Bloomfield, DJ | 1 |
| Brincker, H | 1 |
| Westin, J | 1 |
| Abildgaard, N | 1 |
| Gimsing, P | 1 |
| Turesson, I | 1 |
| Hedenus, M | 1 |
| Ford, J | 2 |
| Kandra, A | 2 |
| Blayney, D | 1 |
| Sinoff, C | 1 |
| Wheeler, H | 1 |
| Simeone, JF | 1 |
| Mellars, K | 2 |
| Bishop, NJ | 1 |
| Chabot, G | 1 |
| Lanoue, G | 1 |
| Houston, S | 1 |
| Rubens, RD | 2 |
| Haworth, CS | 2 |
| Selby, PL | 2 |
| Webb, AK | 2 |
| Mawer, EB | 1 |
| Adams, JE | 2 |
| Freemont, TJ | 2 |
| Bartl, R | 1 |
| Burckhardt, P | 1 |
| Diel, IJ | 2 |
| Fleisch, H | 1 |
| Kyle, RA | 1 |
| Mundy, GR | 1 |
| Koeberle, D | 2 |
| Thuerlimann, B | 2 |
| Senn, HJ | 2 |
| Bacchus, L | 1 |
| Chapurlat, R | 1 |
| Teramoto, S | 1 |
| Matsuse, T | 1 |
| Ouchi, Y | 1 |
| Lortholary, A | 1 |
| Jadaud, E | 1 |
| Berthaud, P | 1 |
| Barişta, I | 1 |
| Trombetti, A | 1 |
| Arlot, M | 1 |
| Thevenon, J | 1 |
| Uebelhart, B | 1 |
| Paule, B | 1 |
| Clerc, D | 1 |
| Brion, N | 1 |
| Abdulla, AJ | 1 |
| McCloskey, EV | 1 |
| Olson, KB | 1 |
| Pienta, KJ | 1 |
| Guillot, M | 1 |
| Eckart, P | 1 |
| Desrosieres, H | 1 |
| Amiour, M | 1 |
| al-Jazayri, Z | 1 |
| Bonabello, A | 1 |
| Galmozzi, MR | 1 |
| Bruzzese, T | 1 |
| Zara, GP | 1 |
| Johnson, IS | 1 |
| Mishra, A | 1 |
| Wong, L | 1 |
| Jonklaas, J | 1 |
| Vitale, G | 1 |
| Fonderico, F | 1 |
| Martignetti, A | 1 |
| Caraglia, M | 1 |
| Ciccarelli, A | 1 |
| Nuzzo, V | 1 |
| Abbruzzese, A | 1 |
| Lupoli, G | 1 |
| Bileckot, R | 1 |
| Touazi, S | 1 |
| Auvinet, B | 1 |
| Le Lain, JC | 1 |
| Coinde, E | 1 |
| David, L | 1 |
| Cottalorda, J | 1 |
| Allard, D | 1 |
| Bost, M | 1 |
| Lucht, F | 1 |
| Stéphan, JL | 1 |
| Arzoo, K | 1 |
| Sadeghi, S | 1 |
| Pullarkat, V | 1 |
| Mercadante, S | 1 |
| Villari, P | 1 |
| Ferrera, P | 1 |
| Dabbene, M | 1 |
| Suzuma, T | 1 |
| Sakurai, T | 1 |
| Yoshimura, G | 1 |
| Umemura, T | 1 |
| Tamaki, T | 1 |
| Yoshimasu, T | 1 |
| Naito, Y | 1 |
| Jagdev, SP | 1 |
| Purohit, P | 1 |
| Heatley, S | 1 |
| Herling, C | 1 |
| Egeler, RM | 1 |
| Brown, RE | 1 |
| Solomayer, EF | 1 |
| Bastert, G | 1 |
| Maksymowych, WP | 1 |
| Jhangri, GS | 1 |
| Fitzgerald, AA | 1 |
| LeClercq, S | 1 |
| Chiu, P | 1 |
| Yan, A | 1 |
| Skeith, KJ | 1 |
| Aaron, SL | 1 |
| Homik, J | 1 |
| Davis, P | 1 |
| Sholter, D | 1 |
| Russell, AS | 1 |
| Ciepłuch, H | 1 |
| Baran, W | 1 |
| Hellmann, A | 1 |
| Groff, L | 1 |
| Zecca, E | 1 |
| Brunelli, C | 1 |
| Boffi, R | 1 |
| Panzeri, C | 1 |
| Cazzaniga, M | 1 |
| Ripamonti, C | 1 |
| Wong, R | 1 |
| Wiffen, PJ | 1 |
| Ryan, PJ | 1 |
| Gibson, T | 1 |
| Fogelman, I | 1 |
| van Holten-Verzantvoort, AT | 2 |
| Zwinderman, AH | 1 |
| Aaronson, NK | 1 |
| Hermans, J | 2 |
| van Emmerik, B | 1 |
| van Dam, FS | 1 |
| van den Bos, B | 1 |
| Bijvoet, OL | 2 |
| Cleton, FJ | 2 |
| Kroon, HM | 1 |
| Harinck, HI | 1 |
| Vermey, P | 1 |
| Elte, JW | 1 |
| Neijt, JP | 1 |
| Beex, LV | 1 |
Clinical Trials (8)
Trial Overview
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Combined Treatment With TNF (Tumor Necrosis Factor) Inhibitor and Pamidronate in AS Patients: Effect on the Radiographic Progression[NCT02313727] | Phase 4 | 30 participants (Anticipated) | Interventional | 2014-12-31 | Not yet recruiting | ||
| A Phase I Pilot Trial to Study the Safety and Efficacy of Concomitant Radiotherapy and Zoledronic Acid for the Palliation of Bone Metastases From Breast Cancer, Prostate Cancer and Lung Cancer[NCT00264420] | Phase 1 | 4 participants (Actual) | Interventional | 2005-12-31 | Completed | ||
| A Randomized, Placebo-Controlled Trial of Alendronate in the Treatment of Polyostotic Fibrous Dysplasia and the McCune-Albright Syndrome[NCT00001728] | Phase 2 | 40 participants (Actual) | Interventional | 1998-08-24 | Completed | ||
| Bone Biopsy for Histomorphometry and Analysis of Bone Marrow Derived Osteoblast and Osteoclast Progenitors to Explore Mechanisms of Decreased Bone Mineral Density in Depression[NCT00001916] | 17 participants | Observational | 1999-03-31 | Completed | |||
| Osteoporosis in Cystic Fibrosis: Study of Bone Mass and Bone Metabolism, and Prospective Randomized Therapeutic Trial.[NCT01812551] | Phase 3 | 171 participants (Actual) | Interventional | 2002-10-31 | Completed | ||
| Prevention of Bone Loss After Pediatric Hematopoietic Cell Transplantation[NCT02074631] | Phase 2 | 80 participants (Actual) | Interventional | 2015-02-28 | Completed | ||
| A 1-year, Multicenter, Open-label Extension to CZOL446H2337 to Evaluate Safety and Efficacy of Zoledronic Acid Twice Yearly in Osteoporotic Children Treated With Glucocorticoids[NCT01197300] | Phase 3 | 25 participants (Actual) | Interventional | 2010-10-25 | Completed | ||
| Prophylactic Radiotherapy of MInimally Symptomatic Spinal Disease (PROMISSeD Trial)[NCT05534321] | Phase 1/Phase 2 | 74 participants (Anticipated) | Interventional | 2022-08-29 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Trial Outcomes
Number of Participants With New Morphometric Vertebral Fractures During the 12 Month Extension Period by Core Treatment Group.
Vertebral morphometry (or concave index) was calculated using the average ratio between mid-height and posterior height from L1 to L4 and performed by a central reader. A new morphometric vertebral fractures during the 12 month Extension Period was defined as a morphometric vertebral fracture present at Month 24 X-ray which was not present at the Extension Baseline (Baseline 2). (NCT01197300)
Timeframe: Month 24 (Visit 15/Final Extension Visit)
| Intervention | Participants (Count of Participants) |
|---|---|
| Core Treatment Zoledronic Acid | 1 |
| Core Treatment: Placebo | 1 |
Number of Participants With New Vertebral Fractures During the 12 Month Extension Period by Core Treatment Group.
New vertebral fractures are defined as fractures of Genant grade 1 or higher that occur at lumbar or thoracic spine from first extension dose infusion to the end of the study in a previously normal vertebra. (NCT01197300)
Timeframe: Month 24 (Visit 15/Final Extension Visit)
| Intervention | Participants (Count of Participants) |
|---|---|
| Core Treatment Zoledronic Acid | 1 |
| Core Treatment: Placebo | 1 |
Long-term Safety of Zoledronic Acid for the Treatment of Osteoporotic Children Treated With Glucocorticoids.
Analysis of absolute and relative frequencies for treatment emergent Adverse Event (AE), Serious Adverse Event (SAE) and Deaths by primary System Organ Class (SOC) to demonstrate that zoledronic acid given long-term, over an additional 12 months from the Core study (CZOL446H2337), is safe for the treatment of osteoporotic children treated with glucocorticoids through the monitoring of relevant clinical and laboratory safety parameters. (NCT01197300)
Timeframe: Baseline 1 (Visit 1 of the Core Study) through Month 24 (Visit 15/Final Extension Visit)
| Intervention | Participants (Count of Participants) | ||
|---|---|---|---|
| On-treatment Adverse Events (AEs) | On-treatment Serious Adverse Events (SAEs) | On-treatment Deaths | |
| Core Treatment Zoledronic Acid | 7 | 3 | 0 |
| Core Treatment: Placebo | 12 | 0 | 0 |
Mean Change From Baseline (Core and Extension) in 2nd Metacarpal Cortical Width at Month 24 by Core Treatment Group.
Left postero-anterior (PA) hand/wrist X-ray were taken at the final visit of Core study and at Visit 15/EOS (Month 24) to assess bone age. The change in 2nd metacarpal cortical width at Month 24 relative to the respective Baseline was calculated. If a fracture of the left upper extremity precluded radiographic imaging, (or precluded this X-ray in the Core study) then the right hand was evaluated for this purpose. In this case, an image of the right hand was carried out at both Visit 8 and at Visit 15/EOS (Month 24). The information was used in the assessment of bone density. (NCT01197300)
Timeframe: Baseline 1 (Visit 1 of the Core Study) and Baseline 2 (Visit 9 of the Extension Study) through Month 24 (Visit 15/Final Extension Visit)
| Intervention | millimeter (mm) (Least Squares Mean) | |
|---|---|---|
| 2nd metacarpal cortical width change from BL1 | 2nd metacarpal cortical width change from BL2 | |
| Core Treatment Zoledronic Acid | -0.04 | -0.09 |
| Core Treatment: Placebo | -0.03 | 0.02 |
Mean Change From Baseline 1 (Visit 1 of the Core Study) in BSAP at Month 18 and 24 by Core Treatment Group.
Bone specific alkaline phosphatase (BSAP) was collected at the final visit Core study at Visit 8, or at 1st infusion visit (Visit 9), and thereafter at Visit 12 (Month 18) and Visit 15 (Month 24) (final Extension study Visit/EOS) of Extension study according to the instructions provided in the Laboratory Manual. The samples were analyzed in batches at the laboratory. Decrease or negative changes from Core baseline indicated a pharmacological response to therapy. (NCT01197300)
Timeframe: Month 18 (Visit 12 of the Extension Study), Month 24 (Visit 15/Final Extension Visit)
| Intervention | nanogram per milliliter (ng/mL) (Least Squares Mean) | |
|---|---|---|
| BSAP Change at Month 18 | BSAP Change at Month 24 | |
| Core Treatment Zoledronic Acid | -13.716 | -9.675 |
| Core Treatment: Placebo | 3.975 | -6.013 |
Mean Change From Baseline 1 (Visit 1 of the Core Study) in Lumbar Spine Bone Mineral Content (BMC) at Month 18 and 24 by Core Treatment Group.
Lumbar Spine Bone Mineral Content (BMC) was determined by the central imaging vendor at the final visit of Core study (Visit 8) or at 1st infusion visit (Visit 9), and thereafter at Visit 12 (Month 18) and Visit 15 (Month 24) (final Extension Study visit/EOS) of Extension study. The methods to be used to measure BMC were described in the respective DXA Manuals. Positive changes from Core baseline indicated an improvement in condition. (NCT01197300)
Timeframe: Month 18 (Visit 12 of the Extension Study), Month 24 (Visit 15/Final Extension Visit)
| Intervention | gram (Least Squares Mean) | |
|---|---|---|
| Lumbar Spine BMC Change at Month 18 | Lumbar Spine BMC Change at Month 24 | |
| Core Treatment Zoledronic Acid | 12.293 | 15.845 |
| Core Treatment: Placebo | 9.933 | 14.666 |
Mean Change From Baseline 1 (Visit 1 of the Core Study) in Lumbar Spine Bone Mineral Density (BMD) Z-score at Month 18 and 24 by Core Treatment Group.
Lumbar Spine Bone Mineral Density (BMD) Z-score was determined by the central imaging vendor at the final visit of Core study (Visit 8) or at 1st infusion visit (Visit 9), and thereafter at Visit 12 (Month 18) and Visit 15 (Month 24) (final Extension Study visit/EOS) of Extension study. The methods to be used to measure Lumbar Spine BMD Z-score were described in the respective DXA Manuals provided by central imaging vendor. Positive changes from Core baseline indicated an improvement in condition. (NCT01197300)
Timeframe: Month 18 (Visit 12 of the Extension Study), Month 24 (Visit 15/Final Extension Visit)
| Intervention | Z-score (Least Squares Mean) | |
|---|---|---|
| Lumbar Spine BMD Z-score Change at Month 18 | Lumbar Spine BMD Z-score Change at Month 24 | |
| Core Treatment Zoledronic Acid | -40.648 | -46.161 |
| Core Treatment: Placebo | -44.348 | -67.913 |
Mean Change From Baseline 1 (Visit 1 of the Core Study) in Serum NTX at Month 18 and 24 by Core Treatment Group.
Serum Cross linked N-telopeptide (NTX) was collected at the final visit Core study at Visit 8, or at 1st infusion visit (Visit 9), and thereafter at Visit 12 (Month 18) and Visit 15 (Month 24) (final Extension study Visit/EOS) of Extension study according to the instructions provided in the Laboratory Manual. The samples were analyzed in batches at the laboratory. Decrease or negative changes from Core baseline indicated a pharmacological response to therapy. (NCT01197300)
Timeframe: Month 18 (Visit 12 of the Extension Study), Month 24 (Visit 15/Final Extension Visit)
| Intervention | nmol BCE/L (Least Squares Mean) | |
|---|---|---|
| Serum NTX Change at Month 18 | Serum NTX Change at Month 24 | |
| Core Treatment Zoledronic Acid | -17.577 | -17.450 |
| Core Treatment: Placebo | -12.916 | -14.891 |
Mean Change From Baseline 1 (Visit 1 of the Core Study) in Serum P1NP at Month 18 and 24 by Core Treatment Group.
Serum Procollagen type 1 amino-terminal propeptide (P1NP) was collected at the final visit Core study at Visit 8, or at 1st infusion visit (Visit 9), and thereafter at Visit 12 (Month 18) and Visit 15 (Month 24) (final Extension study Visit/EOS) of Extension study according to the instructions provided in the Laboratory Manual. The samples were analyzed in batches at the laboratory. Decrease or negative changes from Core baseline indicated a pharmacological response to therapy. (NCT01197300)
Timeframe: Month 18 (Visit 12 of the Extension Study), Month 24 (Visit 15/Final Extension Visit)
| Intervention | nanogram per milliliter (ng/mL) (Least Squares Mean) | |
|---|---|---|
| Serum P1NP Change at Month 18 | Serum P1NP Change at Month 24 | |
| Core Treatment Zoledronic Acid | -169.837 | -228.068 |
| Core Treatment: Placebo | -22.157 | -95.631 |
Mean Change From Baseline 1 (Visit 1 of the Core Study) in Serum TRAP-5b at Month 18 and 24 by Core Treatment Group.
Serum Tartrate-resistant acid phosphatase isoform 5b (TRAP 5b) were collected at the final visit Core study at Visit 8, or at 1st infusion visit (Visit 9), and thereafter at Visit 12 (Month 18) and Visit 15 (Month 24) (final Extension study Visit/EOS) of Extension study according to the instructions provided in the Laboratory Manual. The samples were analyzed in batches at the laboratory. Decrease or negative changes from Core baseline indicated a pharmacological response to therapy. Decrease or negative changes from Core baseline indicated a pharmacological response to therapy. (NCT01197300)
Timeframe: Month 18 (Visit 12 of the Extension Study), Month 24 (Visit 15/Final Extension Visit)
| Intervention | U/L (Least Squares Mean) | |
|---|---|---|
| Serum TRAP-5b Change at Month 18 | Serum TRAP-5b Change at Month 24 | |
| Core Treatment Zoledronic Acid | -2.661 | -2.670 |
| Core Treatment: Placebo | -1.179 | -2.260 |
Mean Change From Baseline 1 (Visit 1 of the Core Study) in Total Body BMC at Month 18 and 24 by Core Treatment Group.
Total body BMC were determined by the central imaging vendor at the final visit of Core study (Visit 8) or at 1st infusion visit (Visit 9), and thereafter at Visit 12 (Month 18) and Visit 15 (Month 24) (final Extension Study visit/EOS) of Extension study. The methods to be used to measure BMC were described in the respective DXA Manuals. Positive changes from Core baseline indicated an improvement in condition. (NCT01197300)
Timeframe: Month 18 (Visit 12 of the Extension Study), Month 24 (Visit 15/Final Extension Visit)
| Intervention | gram (Least Squares Mean) | |
|---|---|---|
| Total body BMC Change at Month 18 | Total body BMC Change at Month 24 | |
| Core Treatment Zoledronic Acid | 387.721 | 496.997 |
| Core Treatment: Placebo | 266.592 | 431.323 |
Percentage of Patients With Reduction in Pain From Baseline 1 (Visit 1 of the Core Study) at Month 15, 18, 21 and 24 by Core Treatment Group.
Pain was evaluated at each visit (at office and telephone visit) at the final visit of the Core study and first visit of the Extension study (Visit 9), Visits 11 (Month 15), 12 (Month 18), 14 (Month 21) and 15 (Month 24) using the Faces Pain Scale-Revised (FPS-R). Children were selecting the face that best fits their pain. The pain score ranged from 0 (No Pain) to 10 (Very Much Pain). The reduction in pain from Core baseline by visit was evaluated based on whether or not patients had a decrease in their FPS-R from baseline. If pain remained the same or worsened from baseline a patient was classified as '0' and if the pain scale decreased then the patient was classified as '1'. (NCT01197300)
Timeframe: Month 15, Month 18, Month 21, Month 24
| Intervention | Percentage of Patients (Number) | |||
|---|---|---|---|---|
| Reduction in Pain at Month 15 | Reduction in Pain at Month 18 | Reduction in Pain at Month 21 | Reduction in Pain at Month 24 | |
| Core Treatment Zoledronic Acid | 55.6 | 30.0 | 30.0 | 30.0 |
| Core Treatment: Placebo | 46.2 | 50.0 | 50.0 | 38.5 |
Reviews
23 reviews available for pamidronate and Pain
| Article | Year |
|---|---|
Pharmacotherapies for Central Post-Stroke Pain: A Systematic Review and Network Meta-Analysis.
Topics: Anticonvulsants; Etanercept; Humans; Lamotrigine; Levetiracetam; Network Meta-Analysis; Pain; Pamidr | 2022 |
Pharmacological interventions for pain in children and adolescents with life-limiting conditions.
Topics: Adolescent; Alendronate; Baclofen; Botulinum Toxins, Type A; Cerebral Palsy; Child; Child, Preschool | 2015 |
QUESTION 1: Should we be using bisphosphonates for osteonecrosis complicating childhood acute lymphoblastic leukaemia?
Topics: Adolescent; Alendronate; Antineoplastic Agents; Bone Density Conservation Agents; Diphosphonates; Fe | 2016 |
Pamidronate treatment in rheumatology practice: a comprehensive review.
Topics: Anti-Inflammatory Agents; Diphosphonates; Humans; Pain; Pamidronate; PubMed; Randomized Controlled T | 2009 |
[Pamidronate in the treatment of bone metastases from breast cancer].
Topics: Ambulatory Care; Animals; Antineoplastic Agents; Bone Neoplasms; Breast Neoplasms; Diphosphonates; D | 2002 |
Conventional treatments for ankylosing spondylitis.
Topics: Adrenal Cortex Hormones; Anti-Inflammatory Agents, Non-Steroidal; Antimalarials; Azathioprine; Dipho | 2002 |
The new bisphosphonate, Zometa (zoledronic acid), decreases skeletal complications in both osteolytic and osteoblastic lesions: a comparison to pamidronate.
Topics: Adenocarcinoma; Biomarkers; Bone Neoplasms; Breast Neoplasms; Clinical Trials as Topic; Diphosphonat | 2002 |
Efficacy of bisphosphonates in the management of skeletal complications of bone metastases and selection of clinical endpoints.
Topics: Bone Neoplasms; Breast Neoplasms; Clodronic Acid; Data Interpretation, Statistical; Diphosphonates; | 2002 |
[Clinical study of bisphosphonates for bone metastasis in breast cancer].
Topics: Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Diphosphonates; Female; Fracture | 2007 |
Bone and cancer: pathophysiology and treatment of metastases.
Topics: Analgesics, Non-Narcotic; Bone and Bones; Bone Diseases, Metabolic; Bone Neoplasms; Breast Neoplasms | 1995 |
Use of bisphosphonates in cancer patients.
Topics: Alendronate; Bone Neoplasms; Bone Resorption; Breast Neoplasms; Clodronic Acid; Diphosphonates; Etid | 1996 |
Analgesic effect of bisphosphonates on bone pain in breast cancer patients: a review article.
Topics: Analgesia; Analgesics, Non-Narcotic; Bone Neoplasms; Breast Neoplasms; Clodronic Acid; Diphosphonate | 1996 |
Rationale for the use of bisphosphonates in breast cancer.
Topics: Bone Neoplasms; Bone Remodeling; Breast Neoplasms; Clodronic Acid; Cost-Benefit Analysis; Diphosphon | 1996 |
[Treatment of pain in oncology].
Topics: Administration, Cutaneous; Analgesics, Opioid; Anesthetics, Dissociative; Diphosphonates; Fentanyl; | 1997 |
Bisphosphonates and breast carcinoma.
Topics: Bone Diseases; Bone Neoplasms; Bone Resorption; Breast Neoplasms; Calcification, Physiologic; Clinic | 1997 |
Bisphosphonates in multiple myeloma.
Topics: Bone Diseases; Bone Resorption; Clodronic Acid; Diphosphonates; Etidronic Acid; Humans; Multiple Mye | 1997 |
Should bisphosphonates be part of the standard therapy of patients with multiple myeloma or bone metastases from other cancers? An evidence-based review.
Topics: Analgesics, Non-Narcotic; Bone Neoplasms; Breast Neoplasms; Clodronic Acid; Diphosphonates; Evidence | 1998 |
Current use of bisphosphonates in oncology. International Bone and Cancer Study Group.
Topics: Analgesics, Non-Narcotic; Bone and Bones; Bone Neoplasms; Bone Resorption; Breast Neoplasms; Clodron | 1998 |
[Bisphosphonates and bone metastases].
Topics: Antineoplastic Agents; Bone Diseases; Bone Neoplasms; Breast Neoplasms; Clodronic Acid; Diphosphonat | 1999 |
Bisphosphonates in multiple myeloma.
Topics: Clodronic Acid; Diphosphonates; Etidronic Acid; Humans; Hypercalcemia; Multiple Myeloma; Pain; Pamid | 2000 |
Treatment of metastatic bone disease in breast cancer: bisphosphonates.
Topics: Analgesics, Non-Narcotic; Antineoplastic Agents; Bone Neoplasms; Breast Neoplasms; Clodronic Acid; D | 2000 |
Bisphosphonates for the relief of pain secondary to bone metastases.
Topics: Analgesics, Non-Narcotic; Antineoplastic Agents; Bone Neoplasms; Clodronic Acid; Diphosphonates; Eti | 2002 |
Bone metastases and tumor-induced hypercalcemia.
Topics: Antineoplastic Agents; Bone Neoplasms; Bone Resorption; Calcitonin; Combined Modality Therapy; Dipho | 1992 |
Trials
53 trials available for pamidronate and Pain
| Article | Year |
|---|---|
A phase II, multicentre trial evaluating the efficacy of de-escalated bisphosphonate therapy in metastatic breast cancer patients at low-risk of skeletal-related events.
Topics: Administration, Intravenous; Biomarkers; Bone Density Conservation Agents; Bone Neoplasms; Breast Ne | 2014 |
Use of bisphosphonates for the treatment of osteonecrosis as a complication of therapy for childhood acute lymphoblastic leukaemia (ALL).
Topics: Administration, Oral; Adolescent; Adrenal Cortex Hormones; Alendronate; Antineoplastic Combined Chem | 2010 |
A comparative study of intravenous ibandronate and pamindronate in patients with bone metastases from breast or lung cancer: effect on metastatic bone pain.
Topics: Bone Density Conservation Agents; Bone Neoplasms; Bone Resorption; Breast Neoplasms; Diphosphonates; | 2011 |
Procollagen type I N-propeptide is a predictor of skeletal morbidity in patients with malignant osteolytic bone disease on bisphosphonates.
Topics: Aged; Antineoplastic Agents; Biomarkers; Bone and Bones; Bone Neoplasms; Collagen Type I; Diphosphon | 2011 |
Pamidronate treatment in bone fibrous dysplasia in children and adolescents with McCune-Albright syndrome.
Topics: Adolescent; Adult; Alkaline Phosphatase; Body Height; Bone and Bones; Bone Density; Child; Diphospho | 2002 |
[Effects of pamidronate disodium (Bonin) combined with chemotherapy on bone pain in multiple myeloma].
Topics: Adult; Aged; Antineoplastic Agents; Bone Diseases; Clinical Trials as Topic; Diphosphonates; Drug Th | 2002 |
Combined analysis of two multicenter, randomized, placebo-controlled studies of pamidronate disodium for the palliation of bone pain in men with metastatic prostate cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Bone Neoplasms; Diphosphonates; Double-Blind | 2003 |
A randomized clinical trial comparing oral alendronate and intravenous pamidronate for the treatment of Paget's disease of bone.
Topics: Administration, Oral; Aged; Alendronate; Alkaline Phosphatase; Biomarkers; Bone and Bones; Calcium; | 2004 |
Duration of bisphosphonate treatment: results of a non-randomised study in patients previously treated with local irradiation for bone metastases from breast cancer.
Topics: Adult; Bone Neoplasms; Breast Neoplasms; Diphosphonates; Disease-Free Survival; Female; Greece; Huma | 2004 |
[Pamidronate in treatment of pain caused by bone metastasis].
Topics: Adult; Aged; Bone Neoplasms; Breast Neoplasms; Diphosphonates; Dose-Response Relationship, Drug; Fem | 2004 |
Pamidronate treatment of less severe forms of osteogenesis imperfecta in children.
Topics: Absorptiometry, Photon; Adolescent; Alkaline Phosphatase; Body Height; Body Weight; Bone and Bones; | 2004 |
Cyclic administration of pamidronate to treat osteoporosis in children with cerebral palsy or a neuromuscular disorder: a clinical study.
Topics: Adolescent; Anti-Inflammatory Agents; Cerebral Palsy; Child; Child, Preschool; Diphosphonates; Drug | 2005 |
[Clinical value of combined therapy with 188Re-HEDP and pamidronate in breast cancer with bone metastasis].
Topics: Adult; Aged; Antineoplastic Agents; Bone Neoplasms; Breast Neoplasms; Carcinoembryonic Antigen; Comb | 2005 |
Comparison of the analgesic efficacy of pamidronate and synthetic human calcitonin in osteoporotic vertebral fractures: a double-blind controlled study.
Topics: Aged; Aged, 80 and over; Analgesics; Bone Density Conservation Agents; Calcitonin; Diphosphonates; F | 2006 |
Pamidronate treatment of steroid associated osteonecrosis in young patients treated for acute lymphoblastic leukaemia--two-year outcomes.
Topics: Adolescent; Adult; Antineoplastic Agents, Hormonal; Bone Density Conservation Agents; Diphosphonates | 2006 |
Bisphosphonate treatment of bone fibrous dysplasia in McCune-Albright syndrome.
Topics: Adolescent; Alkaline Phosphatase; Bone Density Conservation Agents; Child; Child, Preschool; Diphosp | 2006 |
The analgesic effect of pamidronate is not caused by the elevation of beta endorphin level in Paget's disease--a controlled pilot study.
Topics: Aged; Analgesics; beta-Endorphin; Bone Density Conservation Agents; Diphosphonates; Female; Humans; | 2006 |
Phase II trial evaluating the palliative benefit of second-line zoledronic acid in breast cancer patients with either a skeletal-related event or progressive bone metastases despite first-line bisphosphonate therapy.
Topics: Adult; Aged; Aged, 80 and over; Bone and Bones; Bone Density Conservation Agents; Bone Neoplasms; Br | 2006 |
A Phase II trial evaluating the palliative benefit of second-line oral ibandronate in breast cancer patients with either a skeletal related event (SRE) or progressive bone metastases (BM) despite standard bisphosphonate (BP) therapy.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Bone and Bones; Bone Density Conservation Agen | 2008 |
Comparison of different intravenous bisphosphonate regimens for Paget's disease of bone.
Topics: Aged; Diphosphonates; Drug-Related Side Effects and Adverse Reactions; Female; Follow-Up Studies; Hu | 2007 |
Efficacy of pamidronate in erosive degenerative disk disease: A pilot study.
Topics: Adult; Anti-Inflammatory Agents; Diphosphonates; Female; Humans; Infant; Intervertebral Disc Displac | 2007 |
Does pamidronate enhance the analgesic effect of radiotherapy? A randomized trial.
Topics: Analgesia; Antineoplastic Agents; Bone Neoplasms; Diphosphonates; Humans; Pain; Pain Measurement; Pa | 2007 |
Intravenous pamidronate disodium treatment of bone metastases in patients with breast cancer. A dose-seeking study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Ambulatory Care; Analgesics, Opioid; Bone Neoplasms; Bre | 1994 |
A single infusion of bisphosphonate AHPrBP in the treatment of Paget's disease of bone.
Topics: Aged; Aged, 80 and over; Alkaline Phosphatase; Child; Creatinine; Diphosphonates; Female; Humans; Hy | 1994 |
Effects of intravenous pamidronate therapy on Paget's disease of bone.
Topics: Aged; Aged, 80 and over; Alkaline Phosphatase; Calcium; Diphosphonates; Female; Humans; Hydroxyproli | 1994 |
High-dose intravenous pamidronate for metastatic bone pain.
Topics: Bone and Bones; Bone Neoplasms; Diphosphonates; Dose-Response Relationship, Drug; Female; Humans; Hy | 1994 |
Pamidronate for pain control in patients with malignant osteolytic bone disease: a prospective dose-effect study.
Topics: Activities of Daily Living; Bone Neoplasms; Breast Neoplasms; Diphosphonates; Dose-Response Relation | 1994 |
Pamidronate is effective for Paget's disease of bone refractory to conventional therapy.
Topics: Alkaline Phosphatase; Calcitonin; Creatinine; Diphosphonates; Drug Administration Schedule; Drug Res | 1993 |
Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma. Myeloma Aredia Study Group.
Topics: Aged; Diphosphonates; Disease-Free Survival; Double-Blind Method; Female; Fractures, Bone; Humans; H | 1996 |
Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma. Myeloma Aredia Study Group.
Topics: Aged; Diphosphonates; Disease-Free Survival; Double-Blind Method; Female; Fractures, Bone; Humans; H | 1996 |
Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma. Myeloma Aredia Study Group.
Topics: Aged; Diphosphonates; Disease-Free Survival; Double-Blind Method; Female; Fractures, Bone; Humans; H | 1996 |
Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma. Myeloma Aredia Study Group.
Topics: Aged; Diphosphonates; Disease-Free Survival; Double-Blind Method; Female; Fractures, Bone; Humans; H | 1996 |
Metabolic effects of pamidronate in patients with metastatic bone disease.
Topics: Aged; Alkaline Phosphatase; Analysis of Variance; Biomarkers; Bone Development; Bone Neoplasms; Bone | 1996 |
The role of bisphosphonates in the treatment of bone metastases--the U.S. experience.
Topics: Antineoplastic Agents; Bone Neoplasms; Bone Resorption; Breast Neoplasms; Clinical Trials as Topic; | 1996 |
Pamidronate in patients with painful bone metastases, who failed initial treatment with hormones and/or chemotherapy.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Bone Neoplasms; Diphosphonates; | 1996 |
Clinical, biochemical, hematologic, and radiographic responses in Paget's disease following intravenous pamidronate disodium: a 2-year study.
Topics: Aged; Aged, 80 and over; Alkaline Phosphatase; Analysis of Variance; Bone and Bones; Diphosphonates; | 1996 |
Efficacy of pamidronate in breast cancer with bone metastases: a randomized double-blind placebo controlled multicenter study.
Topics: Bone Neoplasms; Breast Neoplasms; Diphosphonates; Female; Humans; Osteolysis; Pain; Pamidronate; Qua | 1996 |
Long-term effects of intravenous pamidronate in fibrous dysplasia of bone.
Topics: Adolescent; Adult; Biomarkers; Biopsy; Bone and Bones; Bone Density; Bone Remodeling; Calcium, Dieta | 1997 |
Bisphosphonates in multiple myeloma.
Topics: Bone Diseases; Bone Resorption; Clodronic Acid; Diphosphonates; Etidronic Acid; Humans; Multiple Mye | 1997 |
High dose pamidronate: clinical and biochemical effects in metastatic bone disease.
Topics: Biomarkers, Tumor; Bone Diseases; Breast Neoplasms; Collagen; Diphosphonates; Female; Humans; Male; | 1997 |
Fitting new modalities into practice guidelines.
Topics: Antineoplastic Agents; Bone and Bones; Bone Neoplasms; Breast Neoplasms; Data Interpretation, Statis | 1997 |
Failure of oral pamidronate to reduce skeletal morbidity in multiple myeloma: a double-blind placebo-controlled trial. Danish-Swedish co-operative study group.
Topics: Administration, Oral; Aged; Anti-Inflammatory Agents; Antineoplastic Combined Chemotherapy Protocols | 1998 |
Long-term prevention of skeletal complications of metastatic breast cancer with pamidronate. Protocol 19 Aredia Breast Cancer Study Group.
Topics: Alkaline Phosphatase; Analgesics; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; | 1998 |
Cyclic administration of pamidronate in children with severe osteogenesis imperfecta.
Topics: Adolescent; Alkaline Phosphatase; Bone Density; Bone Development; Bone Resorption; Calcium; Child; C | 1998 |
Cyclic administration of pamidronate in children with severe osteogenesis imperfecta.
Topics: Adolescent; Alkaline Phosphatase; Bone Density; Bone Development; Bone Resorption; Calcium; Child; C | 1998 |
Cyclic administration of pamidronate in children with severe osteogenesis imperfecta.
Topics: Adolescent; Alkaline Phosphatase; Bone Density; Bone Development; Bone Resorption; Calcium; Child; C | 1998 |
Cyclic administration of pamidronate in children with severe osteogenesis imperfecta.
Topics: Adolescent; Alkaline Phosphatase; Bone Density; Bone Development; Bone Resorption; Calcium; Child; C | 1998 |
Cyclic administration of pamidronate in children with severe osteogenesis imperfecta.
Topics: Adolescent; Alkaline Phosphatase; Bone Density; Bone Development; Bone Resorption; Calcium; Child; C | 1998 |
Cyclic administration of pamidronate in children with severe osteogenesis imperfecta.
Topics: Adolescent; Alkaline Phosphatase; Bone Density; Bone Development; Bone Resorption; Calcium; Child; C | 1998 |
Cyclic administration of pamidronate in children with severe osteogenesis imperfecta.
Topics: Adolescent; Alkaline Phosphatase; Bone Density; Bone Development; Bone Resorption; Calcium; Child; C | 1998 |
Cyclic administration of pamidronate in children with severe osteogenesis imperfecta.
Topics: Adolescent; Alkaline Phosphatase; Bone Density; Bone Development; Bone Resorption; Calcium; Child; C | 1998 |
Cyclic administration of pamidronate in children with severe osteogenesis imperfecta.
Topics: Adolescent; Alkaline Phosphatase; Bone Density; Bone Development; Bone Resorption; Calcium; Child; C | 1998 |
A randomised phase II study of oral pamidronate for the treatment of bone metastases from breast cancer.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Bone Neoplasms; Breast | 1998 |
Severe bone pain after intravenous pamidronate in adult patients with cystic fibrosis.
Topics: Adult; Anti-Inflammatory Agents; Bone Density; Bone Diseases; Cystic Fibrosis; Diphosphonates; Dose- | 1998 |
Pamidronate treatment in patients with malignant osteolytic bone disease and pain: a prospective randomized double-blind trial.
Topics: Absorptiometry, Photon; Adult; Aged; Aged, 80 and over; Analgesics; Anti-Inflammatory Agents; Antine | 1999 |
Effect of multiple intravenous pamidronate courses in Paget's disease of bone.
Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents; Bone Demineralization, Pathologic; Diphosp | 1999 |
Pamidronate prevents skeletal complications and is effective palliative treatment in women with breast carcinoma and osteolytic bone metastases: long term follow-up of two randomized, placebo-controlled trials.
Topics: Aged; Antineoplastic Agents; Bone Neoplasms; Breast Neoplasms; Diphosphonates; Double-Blind Method; | 2000 |
Pamidronate improves the quality of life and induces clinical remission of bone metastases in patients with thyroid cancer.
Topics: Adenocarcinoma, Follicular; Adult; Aged; Analgesics; Anti-Inflammatory Agents; Bone Neoplasms; Bone | 2001 |
Comparison of the effects of intravenous pamidronate and oral clodronate on symptoms and bone resorption in patients with metastatic bone disease.
Topics: Administration, Oral; Adult; Aged; Analgesics, Non-Narcotic; Anti-Inflammatory Agents; Bone Neoplasm | 2001 |
A six-month randomized, controlled, double-blind, dose-response comparison of intravenous pamidronate (60 mg versus 10 mg) in the treatment of nonsteroidal antiinflammatory drug-refractory ankylosing spondylitis.
Topics: Adult; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Arthralgia; Diphosphonates | 2002 |
Combination of pamidronate and thalidomide in the therapy of treatment-resistant multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protoc | 2002 |
The role of disodium pamidronate in the management of bone pain due to malignancy.
Topics: Adult; Aged; Analgesics; Antineoplastic Agents; Bone Neoplasms; Combined Modality Therapy; Diphospho | 2001 |
The effect of supportive pamidronate treatment on aspects of quality of life of patients with advanced breast cancer.
Topics: Activities of Daily Living; Adult; Aged; Aged, 80 and over; Bone Neoplasms; Breast Neoplasms; Diphos | 1991 |
Reduced morbidity from skeletal metastases in breast cancer patients during long-term bisphosphonate (APD) treatment.
Topics: Adult; Aged; Aged, 80 and over; Bone Neoplasms; Breast Neoplasms; Clinical Trials as Topic; Diphosph | 1987 |
Other Studies
63 other studies available for pamidronate and Pain
| Article | Year |
|---|---|
Effects of Pamidronate Disodium Combined with Calcium on BMD Values and Severity of Pain in Elderly Patients with Osteoporosis Based on Mobile Terminal Platform for Internet of Things.
Topics: Aged; Bone Density; Calcium; Diphosphonates; Humans; Internet of Things; Lumbar Vertebrae; Osteoporo | 2022 |
Chronic recurrent multifocal osteomyelitis with a comprehensive approach to differential diagnosis of paediatric skull pain.
Topics: Child; Chronic Disease; Diagnosis, Differential; Female; Humans; Magnetic Resonance Imaging; Osteiti | 2023 |
Therapy with pamidronate in children with osteogenesis imperfecta.
Topics: Adolescent; Alkaline Phosphatase; Bone Density; Bone Density Conservation Agents; Child; Child, Pres | 2017 |
Role of Bone-Modifying Agents in Metastatic Breast Cancer: An American Society of Clinical Oncology-Cancer Care Ontario Focused Guideline Update Summary.
Topics: Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Denosumab; Female; Humans; Medic | 2017 |
Elderly man with mandibular pain.
Topics: Abscess; Aged; Anti-Bacterial Agents; Bone Density Conservation Agents; Drainage; Fever; Humans; Mal | 2019 |
Osteolysis and pain due to experimental bone metastases are improved by treatment with rapamycin.
Topics: Animals; Antibiotics, Antineoplastic; Bone Density Conservation Agents; Bone Neoplasms; Cell Line, T | 2014 |
Case 4: How Much Is Too Much? A Case of Hypercalcemia in a 6-year-old Boy.
Topics: Bone Density Conservation Agents; Calcitonin; Child; Diagnosis, Differential; Dietary Supplements; D | 2015 |
Use of intravenous bisphosphonates in older women with breast cancer.
Topics: Age Factors; Aged; Aged, 80 and over; Bone Density Conservation Agents; Bone Neoplasms; Breast Neopl | 2008 |
Rapid pain relief and marked sclerotic change of multiple bone metastases from a synovial sarcoma after treatment with intravenous pamidronate and chemotherapy.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Density Conservation Agents; Bone Neopla | 2009 |
Pamidronate improves pain, wellbeing, fracture rate and bone density in 14 children and adolescents with chronic neurological conditions.
Topics: Adolescent; Bone Density; Bone Density Conservation Agents; Bone Diseases, Metabolic; Child; Diphosp | 2010 |
Bisphosphonates for bone pain #113.
Topics: Bone Density Conservation Agents; Bone Neoplasms; Diphosphonates; Female; Humans; Imidazoles; Neopla | 2010 |
Palliative treatment of painful bone metastases from non-Hodgkin lymphoma with disodium pamidronate.
Topics: Aged; Antineoplastic Agents; Bone Neoplasms; Combined Modality Therapy; Diphosphonates; Humans; Lymp | 2002 |
[Bisphosphonates in bone metastases. Fewer fractures, less pain].
Topics: Bone Neoplasms; Clinical Trials as Topic; Diphosphonates; Fractures, Spontaneous; Humans; Imidazoles | 2002 |
Clinical evaluation of onset of analgesia using intravenous pamidronate in metastatic bone pain.
Topics: Analgesia; Antineoplastic Agents; Bone Neoplasms; Diphosphonates; Humans; Injections, Intravenous; P | 2002 |
Disease modifying and anti-nociceptive effects of the bisphosphonate, zoledronic acid in a model of bone cancer pain.
Topics: Animals; Bone Density; Bone Neoplasms; Clodronic Acid; Diphosphonates; Female; Hyperalgesia; Hyperes | 2002 |
Scleritis and other ocular side effects associated with pamidronate disodium.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Conjunctivitis; Diphosphonates; Female; Humans; Male | 2003 |
The osteodystrophy of mucolipidosis type III and the effects of intravenous pamidronate treatment.
Topics: Absorptiometry, Photon; Anti-Inflammatory Agents, Non-Steroidal; Biomarkers; Bone Density; Bone Dise | 2002 |
Comment on systemic mastocytosis study.
Topics: Adult; Diphosphonates; Humans; Interferon-alpha; Male; Mastocytosis, Systemic; Middle Aged; Pain; Pa | 2003 |
Effect of pamidronate treatment in children with polyostotic fibrous dysplasia of bone.
Topics: Adolescent; Alkaline Phosphatase; Anti-Inflammatory Agents; Biomarkers; Biopsy; Body Height; Calcium | 2003 |
Bisphosphonates for men with prostate cancer: sifting through the rubble.
Topics: Antineoplastic Agents; Bone Neoplasms; Diphosphonates; Double-Blind Method; Humans; Male; Pain; Pall | 2003 |
Patterns of pain in Paget's disease of bone and their outcomes on treatment with pamidronate.
Topics: Aged; Diphosphonates; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow | 2003 |
Risedronate and pamidronate treatment in the clinical management of patients with severe Paget's disease of bone and acquired resistance to bisphosphonates.
Topics: Administration, Oral; Alkaline Phosphatase; Calcitriol; Clodronic Acid; Diphosphonates; Drug Toleran | 2004 |
Treatment of fibrous dysplasia of bone with intravenous pamidronate: long-term effectiveness and evaluation of predictors of response to treatment.
Topics: Administration, Oral; Adolescent; Adult; Biomarkers; Bone and Bones; Bone Density; Bone Remodeling; | 2004 |
Pamidronate in the treatment of childhood SAPHO syndrome.
Topics: Acquired Hyperostosis Syndrome; Adolescent; Anti-Inflammatory Agents; Child; Diphosphonates; Female; | 2004 |
[Treatment of multiple myeloma with intravenous pamidronate. Pain prevention and suppression of hypercalcemia risk].
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Diphosphonates; Female; Humans; Hypercalcemia; Injec | 2004 |
Pain from myelofibrosis treated with regular pamidronate.
Topics: Adult; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Diphosphonates; Dru | 2004 |
Re: Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer.
Topics: Analgesics; Antineoplastic Agents; Bone Neoplasms; Diphosphonates; Fractures, Bone; Humans; Imidazol | 2005 |
Effects of 3 years of intravenous pamidronate treatment on bone markers and bone mineral density in a patient with osteoporosis-pseudoglioma syndrome (OPPG).
Topics: Abnormalities, Multiple; Adolescent; Adult; Bone Density; Bone Density Conservation Agents; Central | 2006 |
Pachydermoperiostitis and bisphosphonates.
Topics: Adolescent; Bone Density Conservation Agents; Bone Resorption; Diphosphonates; Disease Progression; | 2006 |
Effect of intravenous pamidronate therapy on everyday activities in children with osteogenesis imperfecta.
Topics: Absorptiometry, Photon; Adolescent; Bone and Bones; Bone Density; Bone Density Conservation Agents; | 2007 |
Childhood chronic recurrent multifocal osteomyelitis: pamidronate therapy decreases pain and improves vertebral shape.
Topics: Adolescent; Anti-Inflammatory Agents; Bone Density; Child; Child, Preschool; Diphosphonates; Female; | 2008 |
Extensive personal experience: Paget's disease of bone.
Topics: Animals; Calcitonin; Diphosphonates; Etidronic Acid; Humans; Osteitis Deformans; Pain; Pamidronate; | 1995 |
Long-term effects of intravenous pamidronate in fibrous dysplasia of bone.
Topics: Adolescent; Adult; Alkaline Phosphatase; Diphosphonates; Female; Fibrous Dysplasia of Bone; Follow-U | 1994 |
[Disodium pamidronate (APD) in the treatment of bone metastases].
Topics: Adult; Bone Neoplasms; Breast Neoplasms; Diphosphonates; Humans; Middle Aged; Multiple Myeloma; Pain | 1993 |
Sapho syndrome with femoral hyperostosis. Two case-reports.
Topics: Adult; Antirheumatic Agents; Diphosphonates; Female; Femur; Humans; Hyperostosis; Magnetic Resonance | 1996 |
Role of bisphosphonates in prevention and treatment of bone metastases from breast cancer.
Topics: Analgesics, Non-Narcotic; Antineoplastic Agents; Bone Neoplasms; Breast Neoplasms; Clodronic Acid; D | 1995 |
Treating bone metastases: sparing the patient needless pain.
Topics: Bone Neoplasms; Bone Resorption; Diphosphonates; Humans; Pain; Pain Management; Palliative Care; Pam | 1997 |
The effect of pamidronate on lumbar spine bone density and pain in osteoporosis secondary to systemic mastocytosis.
Topics: Adult; Bone Density; Diphosphonates; Female; Humans; Lumbar Vertebrae; Male; Mastocytosis; Middle Ag | 1997 |
Long-term aminobisphosphonate treatment of fibrous dysplasia: spectacular increase in bone density.
Topics: Adult; Bone Density; Calcium, Dietary; Collagen; Collagen Type I; Diphosphonates; Female; Fibrous Dy | 1997 |
Short-term effects of pamidronate in patients with Gaucher's disease and severe skeletal involvement.
Topics: Adult; Bone Density; Bone Remodeling; Diphosphonates; Female; Gaucher Disease; Humans; Male; Middle | 1997 |
Diagnostic and prognostic value of biochemical markers in malignant bone disease: a prospective study on the effect of bisphosphonate on pain intensity and progression of malignant bone disease.
Topics: Aged; Amino Acids; Biomarkers; Bone Density; Bone Neoplasms; Bone Resorption; Chromatography, High P | 1998 |
Bisphosphonates for metastatic bone pain.
Topics: Analgesics, Non-Narcotic; Antineoplastic Agents; Bone Neoplasms; Bone Resorption; Breast Neoplasms; | 1999 |
The nonsurgical treatment of fibrous dysplasia.
Topics: Adolescent; Bone Density; Calcium; Diphosphonates; Ergocalciferols; Female; Fibrous Dysplasia of Bon | 1999 |
Increased cytokines and pamidronate-induced bone pain in adults with cystic fibrosis.
Topics: Adult; Anti-Inflammatory Agents; Bone Diseases; Cystic Fibrosis; Diphosphonates; Humans; Pain; Pamid | 1999 |
Oral corticosteroids and bone pain after pamidronate in adults with cystic fibrosis.
Topics: Adult; Anti-Infective Agents; Bone Diseases; Cystic Fibrosis; Diphosphonates; Glucocorticoids; Human | 1999 |
Biphosphonates and the flare phenomenon.
Topics: Antineoplastic Agents; Bone and Bones; Bone Neoplasms; Bone Resorption; Diphosphonates; Humans; Pain | 1999 |
[Biosphonates in oncology].
Topics: Bone Neoplasms; Clodronic Acid; Diphosphonates; Fractures, Bone; Humans; Neoplasms; Osteolysis; Pain | 2000 |
Use of pamidronate for acute pain relief following osteoporotic vertebral fractures.
Topics: Acute Disease; Aged; Aged, 80 and over; Analgesics; Diphosphonates; Female; Humans; Middle Aged; Ost | 2000 |
Osteoporosis pseudoglioma syndrome: treatment of spinal osteoporosis with intravenous bisphosphonates.
Topics: Analgesics, Non-Narcotic; Bone Density; Child; Clodronic Acid; Diphosphonates; Female; Fractures, Bo | 2000 |
Use of bisphosphonates in the treatment of prostate cancer.
Topics: Antineoplastic Agents; Bone Neoplasms; Diphosphonates; Humans; Male; Pain; Palliative Care; Pamidron | 2000 |
[Osteogenesis imperfecta: a new, early therapeutic approach with biphosphonates. A case report].
Topics: Age Factors; Alkaline Phosphatase; Bone Density; Diphosphonates; Drug Administration Schedule; Growt | 2001 |
Analgesic effect of bisphosphonates in mice.
Topics: Abdomen; Analgesics, Non-Narcotic; Animals; Anti-Inflammatory Agents; Clodronic Acid; Diphosphonates | 2001 |
Use of bisphosphonates for the treatment of metastatic bone pain. A survey of palliative physicians in the UK.
Topics: Bone Neoplasms; Clodronic Acid; Diphosphonates; Drug Costs; Humans; Pain; Palliative Care; Pamidrona | 2001 |
Prolonged, symptomatic hypocalcemia with pamidronate administration and subclinical hypoparathyroidism.
Topics: Antineoplastic Agents; Bone Neoplasms; Calcitonin; Calcium Carbonate; Diphosphonates; Female; Humans | 2001 |
[Analgesic effect of Pamidronate on bone pain in patient with hypertrophic pulmonary osteoarthropathy].
Topics: Anti-Inflammatory Agents; Antineoplastic Agents; Carcinoma, Squamous Cell; Diphosphonates; Drug Admi | 2001 |
[Chronic recurrent multifocal osteomyelitis in children: report of 17 cases].
Topics: Adolescent; Adult; Anti-Inflammatory Agents, Non-Steroidal; Biopsy; Bone and Bones; Child; Child, Pr | 2001 |
Pamidronate for bone pain from osteolytic lesions in Langerhans'-cell histiocytosis.
Topics: Adult; Diphosphonates; Female; Histiocytosis, Langerhans-Cell; Humans; Osteolysis; Pain; Pamidronate | 2001 |
Pamidronate in incident pain due to bone metastases.
Topics: Aged; Anti-Inflammatory Agents; Antineoplastic Agents; Bone Neoplasms; Breast Neoplasms; Diphosphona | 2001 |
Pamidronate-induced remission of pain associated with hypertrophic pulmonary osteoarthropathy in chemoendocrine therapy-refractory inoperable metastatic breast carcinoma.
Topics: Adult; Breast Neoplasms; Diphosphonates; Female; Humans; Lung Neoplasms; Osteoarthropathy, Secondary | 2001 |
More on pamidronate in Langerhans'-cell histiocytosis.
Topics: Adolescent; Anti-Inflammatory Agents; Diphosphonates; Histiocytosis, Langerhans-Cell; Humans; Male; | 2001 |
More on pamidronate in Langerhans'-cell histiocytosis.
Topics: Anti-Inflammatory Agents; Diphosphonates; Histiocytosis, Langerhans-Cell; Humans; Mevalonic Acid; Os | 2001 |
Beneficial effect of long term intravenous bisphosphonate treatment of osteogenesis imperfecta.
Topics: Absorptiometry, Photon; Adolescent; Biomarkers; Bone Density; Bone Remodeling; Child; Child, Prescho | 2002 |
Bone scintigraphy following intravenous pamidronate for Paget's disease of bone.
Topics: Alkaline Phosphatase; Creatinine; Diphosphonates; Humans; Hydroxyproline; Infusions, Intravenous; Os | 1992 |